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3-Phenyl-2,3-dihydro-1,2-benzisothiazole 1,1 dioxide (NSC108406), 
identified as an HIV-1 reverse transcriptase inhibitor, is chosen for lead 
optimization.  A series of analogues are docked using SYBYL FlexiDock into both 
wild-type (wt) reverse transcriptase (RT) and Tyr181Cys181 (Y181C) RT, from 
the dataset of efavirenz (Sustiva®) bound to the enzyme.  Minimizations using 
genetic algorithms are performed, and the lowest energy conformations are 
evaluated.   Five structures emerge as good fits either in both enzymes or only in 
Y181C RT.  3-(m-Cyclopropylphenyl)- and 3-(isopropylfuranyl)-2-methyl-2,3-
dihydro-1,2-benzisothiazole 1,1-dioxides do not exhibit improved binding in wt RT 
over efavirenz.  In the Y181C pocket, the furanyl ring oxygen is oriented towards 
Cys181, and the cyclopropyl group on the phenyl ring makes a strong contact 
with Tyr183.  Three 3-(alkylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 
1,1-dioxides (ethynyl sultams) make very good contacts in both wt and Y181C 
RT.   
 Synthesis of the ethynyl sultams is attempted using the appropriate 
alkylethynyllithium reagents with saccharin, but 3,3-bisalkylethynyl-2,3-dihydro-
1,2-benzisothiazole 1,1-dioxides are the principal products.  These are 
methylated to give the bisalkylated sultams.  When docked into wt RT, they are 
consistently placed outside the pocket.  In Y181C RT they make similar contacts 
to nevirapine, a first-generation NNRTI.   
 x 
 3-Chloro-1,2-benzisothiazole 1,1-dioxide is then coupled to the 
alkylethynyllithium reagents to give the desired monosubstituted products.   
(R,R)-N-(p-tolunesulfonyl)-1,2-diphenylethylenediamine-rhodium-
(pentamethycycopentadienyl)-Cl [(R,R)-TSDPEN-Rh-Cl], an enantioselective 
catalyst for the reduction of imines, is used in an attempt to produce optically 
active sultams; however, the products are not optically active.  The cyclopropyl- 
and cyclobutylethynyl bonds are reduced to the corresponding alkanes.  These 
new cycloalkylethyl sultams, when docked into RT, exhibit a better fit in Y181C 
than wt RT, similar to that of efavirenz.   
In a study on the mechanism of the enantioselective reduction of 3-alkyl- 
or aryl-imines by (R,R)-TSDPEN-Rh-Cl, a number of imines are docked into the 
catalyst cavity in two different approaches using the “original” approach that 
gives the observed enantioselectivity and the “reverse” approach, which is 
thought to give the opposite enantiomer.  Molecular dynamic studies are carried 
out.   In all 3-(aryl/alkyl)imine sultams, an average of at least 10 kcal/mol energy 
difference is observed between both approaches, showing probable structures 
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I.  Introduction 
A.  AIDS—The Disease 
 Eighty million people are currently HIV (human immunodeficiency virus) 
positive or living with acquired immunodeficiency syndrome (AIDS), and 20 
million lives have already been lost to one of the deadliest diseases known to 
man.  Since its discovery, HIV has spread among 80 million people worldwide.  A 
total 900,000 of these reside in the US, while the rest live in Europe, Asia or 
Africa, where the disease is rampant.1   
In its early days, HIV was thought to target specific communities, such as 
homosexuals and drug abusers.  But now it is known that HIV does not 
discriminate between woman, man or child, and it infects and causes AIDS using 
the same mechanism of action across all races, cultures, classes and political 
ranks.  AIDS is not “a gay disease,” as it was dubbed earlier.  It is largely a 
sexually transmitted disease that has caused a widespread epidemic and a vast 
public health problem that needs to be taken seriously on all levels.  The war 
against AIDS must continue on all battlefields from global and local political 
legislation that provides prevention programs, health care, tests and medication 
to all patients, to scientific research that facilitates the discovery and 
development of new therapeutic candidates.   
B. A Virus Discovered 
 Robert Gallo’s work on interleukin-2 (IL-2) growth factor paved the way for 
his discovery of Human T-Cell Leukemia Virus Type 1 (HTLV-1).  His work at the 
 2 
time was unique and came along when there was a general misguided opinion 
that human retroviruses do not exist and therefore do not cause cancer in 
humans.2  After he isolated HTLV-1, independent studies out of Japan supported 
his results and reported that HTLV-1 caused a leukemia endemic in Japan.  
Gallo’s work in this field changed the view on human retroviruses, and in a way 
played an important role in setting the stage for the discovery of the human 
immunodeficiency virus (HIV).2  
 In the meantime, Luc Montagnier was leading a small virology division in 
the Pasteur Institute in Paris.  Montagnier and co-workers were also interested in 
retroviruses that caused cancer.  In 1982, using Gallo’s IL-2 growth factor 
technique, they were able to isolate a viral DNA sequence from a breast cancer 
patient biopsy, as well as from the patient’s T-cells.  This viral DNA was also 
similar to a sequence isolated from a mouse mammary cancer cell.3 
 In 1981 a report in the Morbidity and Mortality Weekly Report appeared 
describing patients with no immunological response suffering from pneumocystic 
pneumonia.1  Their blood samples showed no helper T-cells or CD4+ T-cells.  As 
more physicians across the US and the world became aware of this disease, 
more reports of such patients came into the Center for Disease Control (CDC).1  
By the summer of 1981 over 100 cases had been identified in the US, and all 
were gay men.  The new disease was dubbed “the gay disease.”  Initially as the 
CDC gathered epidemiological data, it was thought that lifestyle played a roll in 
an individual’s susceptibility to contracting AIDS.  Even a report from a physician 
in Florida were both men and women of Haitian descent displayed similar 
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symptoms did not get rid of the lifestyle notion.  Reports from France by Dr. 
Rozenbaum and from Belgium by Dr. Piot of more AIDS patients started 
emerging.1  Most interesting was the report of some Congolese patients in 
Belgium exhibiting the same symptoms.  In 1983 the CDC sent a team to the 
Congo to look for patients with AIDS.  There they found that men, women and 
children were suffering from the disease.  It was clear now that AIDS is not 
necessarily a new disease, but a newly discovered one, and that this was a 
worldwide health problem.  Many questions needed to be answered.  What 
causes this disease? Where did it come from?  And more importantly, where was 
it going? 
 In the US more patients were being diagnosed with AIDS, but the patient 
profile had changed.  It was no longer gay men only who came in with the 
symptoms, as intravenous drug users were exhibiting suppressed immune 
response.  Then a hemophiliac baby, who had several blood transfusions, 
displayed loss of immune response and inability to breathe due to pneumonia.1  
With this report, the CDC was now certain that AIDS is caused by a virus, 
because a virus is the only particle small enough to pass through the different 
filters used when donated blood is collected from different donors.  They were 
also sure that the blood supply was contaminated.  More reports of hemophilia 
patients developing AIDS started emerging.  About 35,000 Americans had been 
infected from contaminated blood and blood products.1 
 It is important to note here that by the time the first American patient was 
diagnosed with AIDS, 250,000 more Americans were already infected.  And by 
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the time the first African patient was diagnosed, millions of Africans across the 
continent were infected.1 
 Robert Gallo firmly believed that AIDS was caused by a human retrovirus 
similar to HTLV. So his group decided to look for a retrovirus in blood cell 
cultures.  The problem was that their cell cultures died after a few days.  They 
were being consumed by the virus.2   
 In 1982 Francois Brun-Vezeinet, a former student of Montagnier and then 
a member of the virology group in the Pasteur Institute initiated a collaborative 
effort with Montagnier to find the cause of AIDS.  Montagnier’s laboratory was 
well equipped to hunt for lymphotropic retroviruses, so they obtained a lymph 
node biopsy from a young gay man (a patient of Dr. Rozenbaum) and used it to 
grow T-Cell cultures.3 Two weeks later, the cultures tested positive for reverse 
transcriptase (RT) activity.  At the time the only human retrovirus known was 
HTLV, but the virus in Montagnier’s cell cultures tested negative for HTLV 
antibody recognition and could not be precipitated. They were able to precipitate 
it by using the patient’s own serum.  More samples from different patients were 
tested.  Those with full-blown AIDS had a more aggressive form of the virus that 
replicated rapidly and unlike HTLV killed the T-cell cultures.  Finally they isolated 
the virus and provided the first scanning electron microscopy (SEM) picture of 
the human immunodeficiency virus (HIV).3  Montagnier and his colleagues knew 
immediately that this virus was not the same as HTLV.  Its morphology was 
totally different.  It had a cone-shaped center different than that of HTLV.  The 
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new virus pictures matched those of animal lentiviruses, which further confirmed 
that this new virus does not belong to the HTLV genus.3  
 In the meantime Gallo’s team was still looking for an HTLV-related virus in 
AIDS patients.  SEM images of T-cell lines showed that AIDS patients had two 
viruses.  Gallo initially thought that one was a “mature” form of HTLV, the other 
an “aberrant” form.  However, with Montagnier’s publication of SEM images of 
HIV, Gallo now knew that the reason many of his cell lines tested negative for 
HTLV is because they were infected with a completely different virus, and that 
the 5–10% HTLV-positive results came from patients infected with both HIV and 
HTLV.   In 1984 Gallo and co-workers submitted four papers that provided further 
evidence that HIV is the causative agent of AIDS.2  Their work laid the 
groundwork for the development of blood tests that could detect HIV.  This halted 
infection through blood transfusion and shed light on how much of the world’s 
blood supply had been tainted by HIV-positive blood samples.  
 In 1987 azidothymidine (AZT) was the first anti-HIV drug to be approved 
by the FDA for use by HIV patients.4  Today twenty different HIV drugs are 
present on the market.5 
C. The Origins of HIV: A Short Overview 
 HIV belongs to the lentivirus genus of which simian immunodeficiency 
virus (SIV) is a part.  There are five different lentiviurs lineages.  HIV-1 and HIV-2 
come from two different lineages.  In genetic studies HIV-1 clusters with 
chimpanzee SIV (SIVCPZ).
6  Recent evidence suggests that the source of HIV-1 is 
the chimpanzee subspecies P.t. troglodytes.7  HIV-2 clusters with Sooty 
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Mangabeys SIV (SIVSM) and SIVMAC from macaques.  Although SIVMAC was one 
of the first SIV strains isolated, it was later discovered that all macaque infections 
took place in captivity.   Evolutionary evidence suggests that sooty mangabeys 
are naturally infected by SIV and that they are the source of HIV-2.6  Other SIV 
strains are African Green monkeys SIV (SIVAGM), Sykes monkeys SIV (SIVSYK), 
l’Hoest monkeys SIV (SIVLHOEST), and Sun monkeys SIV (SIVSUN).  All of these 
SIV strains have cross-species transmissions as well.   
 Both HIV-1 and HIV-2 have genetic diversity.  HIV-1 has three major 
groups, M, N, O, and the M group has seven subtypes A–J.  HIV-2 on the other 
hand has six subtypes A–F.  At least four independent cross-species 
transmissions caused the formation of these subtypes.8, 9  The origins of HIV-1 
and HIV-2 are still a highly debated topic.  Initially the origins for both viruses 
were estimated to date back as early as 1951,10 but other estimates suggested 
that these viruses may have diverged as primates evolved putting the origin of 
the lentivirus that infected the common ancestor of all apes and Old World 
monkeys at 25 million years ago.11  
 A molecular clock model puts all three viruses, HIV-1, HIV-2 and SIVAGM, 
with a common ancestor 150 years ago.  A molecular clock model uses 
information from different viruses isolated at various times.  By comparing the 
virus sequences and noting the different mutations, a rate of change can be 
estimated.  HIV-1 has three different proteins that evolved at different rates.  
What the molecular clock model does not take into consideration is host-
dependent evolution.6 
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 There is enough evidence that cross transmission causes lentiviruses to 
evolve according to their host.  SIVAGM is an example of a virus evolving 
specifically with its host. There are four species of African Green Monkeys 
dispersed throughout the African continent.  They are the Sabaeus monkeys in 
West Africa, the Tantalus monkeys in Central Africa, the Givets in East Africa, 
and the Vervets from East to South Africa.  Each species is naturally infected 
with SIVAGM, and each clade (evolutionary class) of SIVAGM has its unique 
evolutionary features, rates of evolution and divergence dates, further supporting 
that as each species became infected with SIVAGM.  The evolution of that specific 
strain became independent of the others and more dependent on the host.  It is 
important to keep in mind that both SIV and HIV are parasites, and in order to 
survive they need a host.  So it is only common sense to expect them to evolve 
along with their respective hosts.  The common ancestor of African Green 
Monkeys existed one million years ago, and it was probably naturally infected 
with the common ancestor of SIVAGM.
6
  
 Another example of host-dependent evolution is that of SIVCPZ. 
Chimpanzees are divided to four geographically distinct subspecies, and not 
surprisingly SIVCPZ has four clades,
6 each of these clades is specific to its 
respective chimpanzee subspecies.12 
 The lack of a fossil record for viruses makes it impossible to rely on 
conventional methods in estimating the age of HIV. In the molecular clock model 
the estimation is based on rate of replication and rate of mutation calculations 
without taking into consideration any other factors. The major weakness of this 
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model is that different viral sites may evolve at different rates so this makes 
calculating and predicting the rate of evolution for the whole virus very difficult 
and faulty.  In more recent studies these rate differences were taken into 
consideration, and the final estimation for SIV increased from 100 years to 350 
years and for HIV from 50 years to 150 years.  That is still inconsistent with the 
idea of host-dependent evolution for millions of years. Sharp and co-workers 
published estimations on the date of emergence for the HIV-1 M group.6 Their 
initial work suggested a date around 1960,13 but the first HIV-1 positive blood 
sample was collected in 1959 from a man from Zaire.  The sequence of that virus 
strain suggested an earlier date, possibly the 1940s.  
D. HIV Lifecycle 
1. Overview 
HIV infection begins with binding of the viral envelope glycoproteins to the 
CD4 receptor and one of the chemokine co-receptors, CXCR4 or CRC5 of the T-
lymphocytes. This is followed by virus–cell fusion events that create a small 
opening in the cell membrane through which the viral materials, which include 
viral RNA and reverse transcriptase, are released into the cell.  Once in the cell, 
reverse transcription of the viral genome commences, followed by integration into 
the cell genetic material.  Viral particles are then synthesized within the cell 
complete with a protein coat, and they are released into the body to further infect 
other cells.  Studies have shown that infection proceeds at a very rapid pace.  In 
one study it was apparent that viral DNA integration occurred approximately 
seven hours after infection.14 
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2. Viral entry 
Viral entry into the host cell can be dissected into four major events: (i) 
viral attachment to the cell surface, (ii) binding to the CD4 receptor, (iii) 
interaction of the CD4-envelope glycoprotein complex with entry co-receptors 
CRC5 and CCRX4, and (iv) virus–cell fusion.    
The viral envelope glycoproteins gp120 and gp41 are essential for binding 
and fusion with the host cell.  Gp120 and gp41 are processed from the N-
terminal and C-terminal parts of gp160.  Gp120, the larger of the two molecules, 
lies outside the envelope lipid bilayer and is responsible for binding with CD4 
receptors and chemokine co-receptors and driving viral fusion. 
The Gp120 amino-acid sequence consists of both conserved and variable 
regions (V1–V5).  V1–V4 are exposed loops with disulfide bonds at their base.  
V1–V4 loops respond to antibody activity and are involved in gp120 binding to 
CD4 receptors as well as chemokine receptors.  V1–V3 are involved in co-
receptor binding as well as virus–cell fusion.15  The V3 loop contains 35 amino 
acids in between Cys303 and Cys338, which are joined together by a disulfide 
bond. Mutations in the tip and stem of the V3 loop produced gp120 glycoproteins 
able to bind to CD4 receptors but unable to form syncytia. V3 neutralizing 
antibodies either completely blocked or greatly reduced the ability of HIV-1 
infection.16  More important are mutations on the disulfide bond residues Cys303 
and Cys338.  These rendered gp120 completely inactive.  Mutagenesis studies 
indicate that deletion of the V3 loop from the viral env gene renders HIV 
completely unable to process gp160 to both gp120 and gp41, as well as hinders 
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syncytia formation.  The exact nature of interactions between V3 and the 
CCR5/CXCR4 receptors is not completely understood; however, from the gp120 
core crystal structure and other studies it can be assumed that electrostatic 
interactions between the substrate and receptor do occur.17  
Detailed crystal structures of gp120 bound and unbound to CD4 have 
been published at resolutions as low as 2.5 Å.15, 18, 19  These structures have 
provided more details on the complexity of the binding process, which will 
hopefully lead to the design of anti-HIV binding compounds that can be used in 
therapy.  Although the exact structure of the V1/V2 and V3  loops is still not 
completely resolved, the core structure of deglycosylated gp120 has been 
determined, and the positioning of these three key loops can be deduced, 
allowing for better understanding of their function.  The crystal structure of the 
gp120 core shows that it has two domains that provide the flexibility for receptor-
induced conformational change. The gp120 protein backbone binds to the CD4 
receptor.  The antigenic side chains are not involved in this process.  This allows 
for the alteration of the amino acid side chains without altering the backbone, and 
therefore limits loss of binding affinity to CD4.  Such a feature gives HIV a rich 
antigenic diversity allowing it to escape the immune system.  Another binding 
interaction is the “knob–socket” interaction between protruding amino acids in 
CD4 and holes in gp120.  Such interactions may be possible targets for 
developing binding inhibitors.17  
The heavy glycosylation of gp120 and gp41 proteins presents a challenge 
to the immune system.  Sugars present themselves in the body as “self”, thereby 
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shielding the receptor binding domains of gp120 and not causing an antibody 
response. They also reduce HIV-1 binding to immunoglobulin-like B-cell 
receptors, which limits antibody production altogether.14, 19, 20  
Another important feature in the gp120 binding mechanism is the 
positioning of the V1/V2 and V3 loops.  Although there are no crystal structures 
available for these regions, modeling studies show them forming an umbrella that 
shields the CD4 binding region of gp120.  Presenting the V1/V2 and V3 regions 
to the immune system protects HIV even further, because should an antibody 
succeed in neutralizing these regions, the virus can simply mutate non-essential 
residues and escape the immune response.15, 17, 19, 20   
Gp41, the smaller of the two proteins, lies in the transmembrane (TM) 
region and mediates virus–cell fusion as well as intracellular membrane fusion 
(syncytia formation).  Gp41 shares general structural features with other viral 
fusion proteins: (a) the presence of an N-terminus containing a hydrophobic 
glycine-rich amino acid sequence known as the fusion peptide (FP), and (b) 
Heptad repeats (HR) adjacent to the TM domains and the hydrophobic 
sequences. These are referred to as NHR for N-terminus heptad repeat and 
CHR for C-terminus heptad repeats.21 The three NHRs fold into a coiled-coil 
structure with the three CHRs fitting into the grooves, forming a thermostable six- 
helix bundle. 22 The two termini are joined together by an extended loop.23-25  The 
heptad repeat contains a reoccurring seven amino acid sequence (abcdefg) in 
which the third and fifth positions contain a hydrophobic amino acid.  
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 The HR sequence is highly conserved, and mutagenic studies have 
shown that mutations in this region render HIV-1 unable to complete the 
membrane-fusion process, and therefore are unable to infect the cell. This shows 
the importance of gp41 in the viral infection/replication cycle.22  
 The fusion mechanism is a highly coordinated and regulated process that 
ensures that specific protein lipid interactions will occur at the right time and 
place. If the envelope proteins are activated too early or too late, the virus will be 
unable to infect.22, 26  
 Gp120 binding to CD4 receptor signals the beginning of the viral fusion 
reaction.  Gp41 contains three immunogenic regions, two of which become 
exposed after CD4 binding occurs. The first region is the loop connecting the 
NHR’s and CHR’s and lie between residues 598 and 604, and the second is in 
the CHR helix residues 644–663. The third region contains amino acids 656–671 
and lies in the transmembrane domain.23, 27 
 More dramatic conformational changes are observed after co-receptor 
binding occurs.  Melikyan and co-workers showed that co-receptor binding is 
necessary in order for fusion to proceed.28 The formation of the metastable six-
helix bundle overcomes a large energy barrier and brings the two membranes 
closer together; however; lipid bilayer membranes have many repulsive forces 
between them.  To overcome this energy barrier gp41 drives this process by 
presenting a hydrophobic region in its FP that inserts itself into the cellular 
membrane causing it expand.22,23 
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The fusion process has been shown to be multistep.  In the first step the 
outer monolayer is fused. In the second step a rupture of the inner monolayer 
occurs creating a fusion part through which the viral materials pass into the 
cellular cytoplasm.  The FP stabilizes this complex; in a study a sequence of 
amino acids taken from the FP were shown to encourage lipid mixing.23  Gp41 is 
attached to the viral membrane by a transmembrane region; the TM is preceded 
by a tryptophan-rich region.  It is not clear how these tryptophan residues 
contribute to the fusion process, but mutational studies have shown that this 
region is important for successful fusion.22, 23, 29 Once the viral materials are in 
the cell, reverse transcription begins.  
3. Reverse Transcription 
HIV has a total of nine genes encoded onto two identical strands of 
genomic RNA.  Following infection, one of these mRNA strands is converted to 
viral materials through a process called reverse transcription.  Initially a reverse 
transcription initiation complex (RTIC) is formed.   At the heart of reverse 
transcription is HIV reverse transcriptase (RT), a heterodimer composed of p66 
and p51 subunits.30  Both of these subunits are encoded by the viral pol gene, 
and are expressed as one gp160 subunit.  A viral aspartyl protease cleaves the 
gp160 precursor into the functional heterodimer p51/p66. Both p66 and p51 
subunits are essential in viral replication; together they form a stable dimer that is 
able to carry DNA transcription to completion.  Crystal structures have identified 
two dimerization sites.  The first one is a series of leucines between residues 283 
and 310. The second is a series of conserved tryptophans in the connection 
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subdomain between residues 399 and 414. In crystal structures of RT bound to 
dsDNA, these tryptophan series in both dimers are in close proximity to each 
other.  Synthetic peptides derived from this region inhibit RT dimerization and 
enzymatic activity.31 
  P66 resembles a right hand with a palm, fingers, thumb, and connection 
domains (See Figure 1). It also contains the active site and the RNase H site in 
its N-terminus and C-terminus, respectively.  P51 is analogues to p66, but it lacks 
the RNase H site (C-terminus) 31-34  P51 has no catalytic activity; its main function 
is to provide structural support for p66.  Crystal structures of bound and unbound 
reverse transcriptase have shed some light on the conformational changes that 
occur when the enzyme is bound to an inhibitor, to a double-stranded DNA 
(dsDNA) and to a polypurine RNA:DNA double strand.33-39  
Understanding the RT mechanism of action in its entirety is essential in 
RT inhibitor design.  The major conformational change between the bound and 
unbound reverse transcriptase is the positioning of the thumb.  In the unbound 
RT, the thumb is in an upright position, in close proximity to the fingers 
subdomains.  Two main points of contact have been identified: a bond between 
Arg78 in the fingers and the main chain of the thumb, and a nonpolar interaction 
between Phe61 in the fingers subdomain and Leu289.  These interactions are 
small in size and weak in strength allowing the thumb freedom of movement to 
make the necessary conformational changes.32  The RT/dsDNA and 
RT/RNA:DNA complexes have the same conformations, with the fingers and 













Figure 1. Reverse transcriptase bound to efavirenz in the allosteric binding 
















palm subdomains interacting heavily with the substrates present in the 
catalytic cavity.34, 39  
It is clear that RT is a flexible enzyme able to undergo necessary 
conformational changes during its catalytic activity. This feature of reverse 
transcriptase makes it an attractive target for drug design. (For a detailed 
discussion on NNRTI mechanism of action, refer to the non-nucleoside reverse 
transcriptase inhibitors (NNRTI) section below.)` 
 DNA synthesis has three major steps that are catalyzed by RT: (i) RNA-
dependent DNA polymerization, where the RNA:DNA hybrid is formed, (ii) RNase 
H degradation of the RNA template, (iii) DNA-dependent DNA polymerization; the 
dsDNA is formed in this stage and is ready to be integrated into the host 
genome.31, 36  Reverse transcription is initiated from the primer binding site 
(PBS).  PBS is comprised of an 18-nucleotide viral genome sequence.31 The 
reverse transcription initiation complex (RTIC) is then formed. Its structure is still 
not properly characterized; however, attempts to fully characterize it are 
underway.  HIV is a parasite, so naturally it would require assistance from its host 
cell machinery to complete its replication cycle.  For example, the RTIC is formed 
outside the host cell nucleus; however, in order for DNA transcription to be 
complete, the complex needs to be moved from the cytoplasm to the nucleus. 
Other cellular proteins seem to regulate HIV replication. The cellular protein 
barrier-to-autointegration factor (BAF) inhibits viral DNA from integration into 
itself. The structure of BAF is still unidentified.  Cellular DNA replication 
processes are reprogrammed as early as 30 minutes after infection, which 
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suggests some sort of communication resulting from viral binding to the CD4, 
CCR5 and CCRX4 receptors.  Once the new viral DNA strand is synthesized, 
integration begins.31 
4. Integration 
 Integration is essential for retroviral replication.  The linear-strand DNA, 
the product of reverse transcription, is the substrate for HIV-1 integrase.  Once 
replication is complete, a pre-integration complex forms.  Isolates of this complex 
contain viral DNA, reverse transcriptase, nucelopcapsid, integrase, and two 
cellular proteins: high-mobility-group HMG-I(Y), and BAF (barrier-to-
autointegration factor).  Retroviral pre-integration complexes either enter the 
nucleus through the nuclear pore or wait until the nuclear membrane dissolves 
during cellular division.40  
Integrase binds to the viral DNA and cleaves its 3′-end groups, resulting in 
the removal of two nucleotides from each end, a reaction called 3’-end 
processing.  The result is the exposure of the 3′-end hydroxyl groups where the 
host DNA will be connected.  The second step is the insertion of the exposed 
viral DNA into cellular DNA.  There is no site specificity for this integration step, 
so it could occur anywhere on the cellular DNA.  Both 3′-end processing and 
DNA strand transfer occur by a one-step mechanism.41, 42  In 3′-end processing 
water is used as a nucelophile.  It is thought that DNA strand transfer occurs in a 
similar fashion.  Although both steps are chemically similar, their binding to the 
integrase active site must be different, because in the DNA strand transfer, both 
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viral and cellular DNA must be bound to the enzyme.40, 41, 43  The exact 
mechanism of these two steps is still not very clear.  
 Unlike reverse transcriptase, a complete crystal structure of HIV-1 
integrase has yet to be obtained.  However, through protease digestion and 
functional complementation studies, it was determined that HIV-1 integrase 
contains three domains: the N-terminal domain, the catalytic core domain,and the 
C-terminal domain. Each of these domain structures has been determined by 
crystallography and NMR studies.44-46 
 The N-terminus consists of 50 amino acids between residues 1 and 50. It 
is essential for integrase activity. The main residues involved in integration are 
the four conserved amino acids His2Cys2; this motif is characteristic of zinc- 
binding sites.40, 41, 43 Mutations to any of these residues reduce the N-terminus’s 
ability to bind to zinc and greatly affect integrase activity. Crystal structures and 
NMR structures have been determined; the N-terminal region has four helices, 
stabilized by hydrophobic interactions in the upper region, and by the zinc ion in 
the lower region.41  
 The C-terminus is the least conserved of all three domains. It is comprised 
of 80 amino acids between residues 213 and 288. It binds DNA nonspecifically, 
and its deletion leads to complete loss of 3’-end processing.  NMR studies 
showed a five-strand β-barrel.46, 47 It is not clear what the exact functions of the 
N- and C-termini domains are in the integration reaction.  Mutations to either 
domain leads to low activity in the enzyme, or in some cases to complete 
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inhibition.  A complete crystal structure may help explain the functions of these 
two domains.16  
 The catalytic core domain is the best characterized and studied of all three 
domains.  It is comprised of 162 amino acids lying between the residues 50 and 
212.40, 43  It also contains the catalytic triad of acidic residues D, D–35-E. In HIV-1 
integrase, this motif corresponds to Asp64, Asp116 and Glu152.41 Mutations in 
this motif severely deplete or completely abolish integrase activity.41   X-ray 
crystallography of the core domain revealed a five-strand β-sheet and six α-
helices.48, 49  In the crystal structure the catalytic triad residues are in close 
proximity to each other; they bind divalent metal ions either Mg2+ or Mn2+.  The 
other residues of the catalytic core region exhibit great flexibility, suggesting that 
DNA binding is required to bring the triad into close contact with each other to 
ensure proper metal binding.  Metal binding is required for full integrase activity. 
While crystal structures have shown metals bound in the catalytic site and in the 
N-terminus, it is not clear if other metal binding sites are present.43 More studies 
are required.   
 As mentioned above, each of the HIV-1 integrase domains have been well 
characterized; however, there are no crystal structures of the three domains 
together, bound or unbound to substrate DNA.  Such a structure will help 
understand the interactions between these domains and their effect on 
integration.   
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After integration, synthesis of the viral poly-protein is accomplished using 
cellular machinery. Cleavage of this large poly-protein into viral proteins is 
catalyzed by HIV protease.  
5. Cleavage of Viral Proteins Catalyzed by Protease  
 HIV protease is a homodimer made up of 99 residues each.  Although the 
crystal structure on the unbound enzyme appears to be symmetrical, HIV 
protease is an asymmetrical enzyme.  In fact similar monomer regions are not 
identical.  The active site is located at the bottom of the dimerization site and is 
covered by two flexible “flaps” of β-hairpins.  The β-hairpin flexibility is necessary 
for substrate binding and product release as well as inhibitor activity.50  Each 
monomer contributes one of the catalytic aspartic acids.  Each catalytic triad in 
both monomers contains Asp25-Thr26-Gly27.  Both triads are stabilized by a 
hydrogen-bond network.51 And the aspartic acid residues are close to each other 
in a coplanner position.52 The hydrolysis mechanism begins with activation of a 
water molecule, followed with a nucleophilic attack by water on the scissile bond 
to form a tetrahedral intermediate. The tetrahedral intermediate then breaks 
down aided by proton transfer to give the desired amino and carboxylate 
products.50  
E. Anti-HIV Chemotherapy 
The diversity of enzymes and receptors involved in the HIV lifecycle 
present multiple targets for drug design.  Perhaps one of the biggest challenges 
in designing new anti-HIV compounds arises from its tendency to mutate at high 
rates.  HIV, particularly reverse transcriptase, is error prone with no correction 
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mechanism set in place.  Once patients are exposed to drugs that are active 
against wild-type HIV, mutant strains that are resistant to therapy are selected.    
As described above in detail, HIV infection begins with cell attachment and 
binding to CD4 receptors, followed by co-receptor binding, virus–cell membrane 
fusion, replication, integration and then synthesis of new viral particles.  Each of 
these processes has a specific enzyme or receptor, and each of these targets 
can be considered for anti-HIV therapy.   
 Several anti-HIV compounds are being studied at different levels of 
development. I have attempted to give a short review on the different inhibitors 
present with a main focus on transcriptase inhibitors, in particular non-nucleoside  
reverse transcriptase inhibitors (NNRTIs). 
1. Cellular CD4 Receptor Down-Modulators 
 The CD4 receptor is the main target for HIV entry into the cell.   
Cyclotriazadisulfonamide (CADA, see below) was shown to inhibit HIV infection 
by down-modulating CD4 receptor expression on cell surfaces. CADA is specific 
for CD4 down-modulation and does not affect other receptors such as CXCR4 
and CCR5.53 It does not directly bind to the receptors, but appears to be involved 
in the down-regulation of CD4 expression on cell surfaces.54 In a recent study 
CADA exhibited the ability to work synergistically with other anti-HIV drugs such 
as nucleoside reverse transcriptase inhibitors, non-nucleoside reverse 






































2. Virus Attachment Inhibitors 
 Mannose-specific plant lectins from Galanthus nivalis (GNA) and 
Hippeastrum hybrid (HHA) have shown activity against viral envelope 
glycoprotein gp120.  Exposure to these lectins produced HIV strains with a 
mutant gp120, but not gp41.  These compounds (proteins) are unique in their 
structure, are of low toxicity, and are currently being considered as microbicides 
to be used topically.56, 57  Another potential microbicide is the protein cyanovirin-
N, an 11-kDa protein isolated from the cyanobacterium Nostoc ellipsosporum.  It 
has a unique affinity for gp120 and inhibits both CD4-dependent and -
independent binding.58-60  BSMS378806 {(4-benzoyl-1-[4-methoxy-1H-pyrrol[2,3-
b]pyridin-3-yl]oxoacetyl)-2-(R)-methylpiperazine}, another CD4 antagonist, has 
been identified as a new class of HIV attachment inhibitors.  It has exhibited 
inactivity against CD4 independent viral entry, which suggests that it interferes 
specifically with CD4–gp120 interactions.  It has shown great bioavailability and 





















3. CXCR4 and CCR5 Antagonists 
 After CD4 binding, gp120 interacts with either CXCR4 or CCR5 receptors. 
In clinical studies AMD3100, a bicyclam CXCR4 antagonist, exhibited inhibition 
against X4 and X4/R5 HIV strains.  A dose as low as 5 µg/kg/h in individuals with 
X4 or X4/R5 resulted in complete loss of viral infection within ten days.  Other 
bicyclams are being pursued as potential candidates.  QSAR studies revealed 
that the presence of both macrocyclic cyclam rings is not necessary for anti-HIV 
potency.  AMD3465 has only once cyclam ring and still possesses comparable 



























TAK779 is the first nonpeptidic CCR5 antagonist identified to block HIV infection 
at nanomolar concentrations.  Unfortunately, it has very low oral bioavailability 
and causes severe irritation at the injection site.66  Further research led to the 
discovery of the bioavailable TAK220.  The structure of TAK220 is not yet 







  SCH351125 was the first CCR5 antagonist advanced to clinical 
studies.  It has the ability to reduce viral load in patients not receiving any other 
antiviral agents.  SCH351125, SCH350581 and TAK779 bind to a putative 
binding pocket in the TM helices 1, 2, 3 and 7.67-69  
Two other CCR5 inhibitors worthy of mentioning are UK427857 and MRK-
1.  UK427857 depletes viral load levels ten days after administration and 
sustains these low levels ten days after therapy was stopped.  It is already in 
clinical trials and may become a once-a-week pill in HIV therapy.  MRK-1 has 
high potency against R5 HIV strains, and it showed great potential as a vaginal 































































4. Viral Cell Fusion Inhibitors 
 Following co-receptor binding, gp120 dissociates from the viral envelope 
to expose gp41, which initiates the virus–cell membrane fusion process.   
Enfuvirtide, also known as T-20, DF-178, and Fuzeon, is a synthetic 36-amino 
acid peptide corresponding with residues 127–162 of gp41.  Initial clinical trials 
—supported by later studies in North America, South America and Europe—
showed the ability of this peptide to lower viral load by 1.5–2.0 fold during 15 
days of treatment.72 Unfortunately Enfuviritide has to be administered through an 
injection twice daily and causes injection-site irritation.  It is also worth noting that 
large-scale peptide synthesis is costly.73, 74 
5. HIV Integrase Inhibitors 
 There is no known cellular homologue for HIV integrase; therefore, this is 
potentially a good therapeutic target.  The structure of the HIV integrase core 
domain complexed with an inhibitor was described recently, leading to the design 
of several diketoacids such as L-708, 906 and L-731,988, which act as inhibitors 
for the covalent bond formation between the 3′-end of viral DNA and cellular 
DNA.  In a study these inhibitors were able to stop infection after seven hours.  
This further supports their involvement in the later stages of HIV replication.75 
Unfortunately, repeated exposure to these diketoacids resulted in mutant 









6. HIV Protease Inhibitors 
 HIV protease is responsible for the cleavage of viral precursor 
polyproteins to the structural proteins: p17, p24, p7, p6, p2, p1, and the functional 
proteins: protease (p11), RT (p51/p66) and integrase (p32).  Protease inhibitors 
stop this process and prevent the formation of the viral particles.  The protease 
inhibitors currently approved for therapy carry the same structural feature, a 
hydroxyethylene bond.65  Astanavir, an aza-dipeptide analogue was approved for 
marketing by the FDA in 2003.  It displayed a favorable profile to resistant PI 
strains.78, 79  
The most recently approved PI by the FDA is darunavir (TMC-114), which 
was developed by structure-based design studies.  The main objective of these  
studies was to design a drug that retains its activity against multidrug-resistant 
(MDR) viruses.    GRL-02031 is another analogue of darunavir coming from the 
same group that developed the other two PIs.  The structure of this latest 
compound has not been revealed.  Darunavir was approved for use in MDR 





























7. Reverse Transcriptase Inhibitors: 
(a) Nucleoside/Nucleotide reverse transcriptase Inhibitors (NRTIs, NtRTIs). 
Upon conversion to their triphosphate form, they inhibit RT competitively 
by causing chain termination. They cause mutations in RT, for example 
some Zidovudine (AZT) resistant RTs are capable of removing the 
blocked primer from the active site.80,81    
(b) Non-nucleoside  reverse transcriptase inhibitors (NNRTIs): NNRTIs are 
structurally diverse.  They bind to an allosteric pocket 10–15 Å away from the 
active site and cause conformational changes in the enzyme, rendering it 





























design of NNRTIs; they have also played an instrumental role in 
understanding the mechanism of resistance.80   
This section will discuss all three inhibitors, focusing mostly on NNRTIs.   
(a) Nucleotide and Nucleoside Reverse Transcriptase  Inhibitors (NtRTIs 
and NRTIs).  NtRTIs have one phosphate group, so they only require two 
phosphorylation steps to become biologically active against HIV RT. They are 
competitive inhibitors that bind to the RT active site and terminate chain 
elongation.  They have been shown to be very useful in patients with resistant 
strains of HIV. For example tenofovir, also known as Viread showed a 
reasonable reduction in HIV RT levels through week 96.64 Tenofovir is a prodrug 









Azidothymidine (AZT)  (Figure 2) was the first drug to be approved by the 
FDA for AIDS therapy.4  It exhibited efficacy in lowering mortality rate and 
reducing the frequency of opportunistic infection during an administration period 





















progression and lowered viral load significantly. Although AZT caused severe 
side effects such as bone marrow suppression, its therapeutic abilities were far 
more valuable than its side effects.  The approval of AZT changed HIV infection 
from a definite death sentence to a chronic disease.  Following AZT, 2′,3′-
dideoxycytidine (DDC) and 2′,3′-dideoxyinosine (DDI) were reported to have anti- 
HIV activity. Both were effective in adults and children and were later approved 
by the FDA; however, their approval came with restrictions.  DDC was only to be 
administered in combination with AZT, and DDI was only approved for patients 
who have developed resistance or intolerance to AZT.82, 83 Another NRTI that 
was FDA approved for anti-HIV therapy is 2′,3′-didehydro-2′,3′-dideoxythymidine 
(D4T, stavudine, Zerit).  In more recent years other NNRTIs have emerged to 
play a key role in combination HIV therapy.  Emtricitabine, 2′,3′-dideoxy-3′-thia-5-
fluorocytidine ( (-)-FTC) was approved by the FDA in July 2003.  It has proved to 
be one of the best HIV drug candidates on the market because it works 
synergistically with a variety of anti-retrovirals, has a long cell half life, and 
therefore can be administered once daily.  It also has excellent bioavalability and 
has 4–10-fold higher in vitro efficacy compared to other NRTIs.65 Figure 2 shows 
structures of different NRTIs.  
(b) Non-nucleoside  Reverse Transcriptase Inhibitor s.  HEPT (1-[(2-
hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine) and TIBO (4,5,6,7-
tetrahydroimidazole[4,5,1-jk][1,4]benzodiazepine-2(1H)-one and –thione) are the 




































































exhibited specific activity against HIV-1, but not HIV-2, and they were identified 
as reverse transcriptase inhibitors.84 
HEPT was originally tested in 1987 for its activity against herpes simplex 
virus (HSV). It was found to be inactive against HSV; however, it displayed 
marked activity against HIV-1 RT.  Following the original HEPT compound (TS-II-
25), other derivatives were synthesized such as E-BPU and E-EBU-dM.  The 
most significant HEPT derivative of all is MKC-442 (also known as I-EBU or 
emivirine).  It was designed using structure–activity relationship studies.  In early 
clinical studies, emivirine exhibited great bioavailability and no mitochondrial, 
bone marrow or reproductive toxicity.  It was moved quickly to phase II studies; 
unfortunately, its development was discontinued.85 Further SAR studies led to the 
development of more flexible HEPT derivatives such as TNK-6123.  The major 
change in TNK-6123 is the presence of a cyclohexylsulfonyl group on C6 as 
opposed to a benzyl group.  This was thought to give a larger range of motion for 
the compound so it can adapt to mutated RT pockets.  This proved to be true as 
TNK-6123 showed 30-fold increase in activity as compared to MKC-442, and it 
maintained activity against the K103N and Y181C mutants.37 Another set of 
HEPT derivatives are the 2-alkoxy-6-benzyl-3,4-dihydro-4-oxopyrimidines 
(DABOs) and 2-(cyclohexylsulfanyl)-3,4-dihydro-5-mehtyl-6-(3-methylbenzyl)-4-
oxopyrimidines (S-DABOs).  A few of these compounds had comparable potency 
against HIV-1 RT to that of MKC-442, but none superceded it.  These 
compounds are considered to be good candidates for microbicide use.  Unlike 
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their nucleoside reverse transcriptase counterparts, they do not just delay HIV 
replication.  They completely suppress it for up to 40 days.86 
In 1989 TIBO derivatives were discovered through a national screening 
program.  TIBO’s discovery led to the characterization of the allosteric pocket in 
which NNRTIs bind, now known as the non-nucleoside  inhibitor binding pocket 
(NNIBP).87 Interestingly, TIBO and HEPT were structurally different; however, 
they shared some common features.  Both had a bridge or body, and two 
hydrophobic (either aromatic or aliphatic) “wings.”  Crystallographic studies 
proved that these compounds took on a butterfly-type conformation when bound 
in NNIBP.88, 89 Following TIBO and HEPT, derivatives of other structurally 
unrelated compounds were identified as NNRTIs.  Three were approved by the 
FDA, nevirapine (Verimune), delivaridine (Rescriptor) and efavirenz (Sustiva).85   
NNRTIs have a unique specificity to HIV-1 RT regardless of the natural 
substrates present in the active site. This suggests that these inhibitors make 
contact within an enzyme site that is independent of the active site. They are also 
very specific to HIV-1 RT, and display little to no activity against HIV-2 SIV or 
cellular DNA polymerases α,β and γ.  Chimeric enzymes of HIV-1/HIV-2 RT and 
HIV-1/SIV RT have been reported.  The exchange of certain amino acids in HIV-
2 and SIV with HIV-1 residues renders these RTs more sensitive to NNRTIs.90-94 
This suggests that amino acids that are present in HIV-1 and not in HIV-2 or SIV 
are important for NNRTI activity.  Although this feature poses a challenge in 
making NNRTIs that are active against both HIV-1 and HIV-2 RTs, it also 
contributes to their low toxicity and high bioavailability.5, 95-101 It is worth noting 
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that NNRTIs active against wt HIV-1 RT have also exhibited activity against 
some mutant HIV-2 RT. The main difference between HIV-1 and HIV-2 RT is the 
residues forming the allosteric binding pocket.  In wt HIV-1 RT these are mainly 
hydrophobic aromatic residues, while in wt HIV-2 RT they are primarily aliphatic 
residues.  In some mutant HIV-2 RT stratins, some residues mutate to aromatic 
hydrophobic amino acids, which makes it easier for wt active NNRTIs to bind; 
therefore, some activity is observed.102, 103 Figure 3 shows structures of relevant 
NNRTIs.  
F. The Non-nucleoside  Reverse Transcriptase Inhibi tor Binding Pocket 
NNRTIs bind to an allosteric pocket located 10–15 Å away from the active 
site that is related structurally and functionally to the active site (Figure 4). The 
pocket lies in the p66 palm domain. It is mainly a hydrophobic pocket comprised 
of the β-sheet (β4,β7,β8), more specifically amino acids 105–110, 179–191 and 
β9,β10 and β11 amino acids 224–241, as well as residues 98–104 preceding β4 
and residues 138,139,141 and 318.  The roof of the pocket is lined by aromatic 
residues Tyr181, Tyr188 and Trp229. The walls are lined with Leu100, Val106 
and Leu234; the floor contains the Lys101–Lys103 domain.  The putative 
entrance of the NNIBP is thought to consist off Pro-95, Leu100, Lys101, Lys103, 
Val179 and Tyr181.104  These residues are involved in an intricate hydrogen-
bond network that might act like a “gatekeeper” keeping inhibitors out.  Inhibitors 
that are successful in entering the pocket must be able to overcome the energy 
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studies suggest that this could be accomplished by inhibitor–residue hydrogen 
bond formation or very strong hydrophobic interactions.104. 
Pro225 and Pro236 form the mouth of the pocket which is thought to essentially 
“close the door” after NNRTIs have entered.87, 105, 106  Glu139, Thr138 of p55 play 
a structural role and lie left of the pocket.33, 38, 107, 108 In general a NNRTI causes 
a conformational change in the β-sheet of p66 subunit locking the catalytic triad, 
Asp110, Asp185, and Asp186, into an inactive conformation similar to that in the 
noncatalytic p55 subunit, as well as locking the thumb subdomain into the 
inactive upright position.105  The binding pocket does not exist in the unbound 
RT.  In the presence of a NNRTI dramatic conformational changes occur in the 
pocket residues.  The most noticeable change is the rotation of Tyr181 and 
Tyr188 side chains upwards towards the catalytic triad and the β-sheet, formed 
by β4,β7, and β8, shift ~2 Å.104  This results in a decrease in catalytic activity and 
is considered to be the basis of NNRTI inhibition.5, 37, 87, 105, 109  
Although structurally diverse, most NNRTIs adopt a butterfly conformation 
when bound to HIV-1 RT.5  Schafer and co-workers were first to provide 
evidence of such conformation.88  At the time no crystal structures of NNRTIs 
bound to HIV RT were available; however, through conformational studies of 
three inhibitor crystal structures, they found that all three inhibitors adopt a 
rooftop-like conformation, or “butterfly conformation.”  Later on, many other 
















for a compound to fit the butterfly conformation are (i) two π-systems, (ii) a body 
or bridge that connects these two systems, usually with a thiocarbonyl, carbonyl, 
or sulfonyl moiety, (iii) a methyl, or alkyl, group on the meta-position of the 
extended π-system.   The key feature that all these inhibitors share is the rigid 
ring structure.88 In more flexible NNRTIs the butterfly conformation is less 
obvious, or in some cases nonexistent.5  
Each NNRTI differs slightly in its interaction with the binding pocket.  The π–π 
interactions with Tyr181, Tyr188, Trp229, and Tyr318 are the most important 
interactions, followed by electrostatic interactions with Lys101,103 and Glu138.  
With the exception of nevirapine, all NNRTIs form hydrogen bonds with at least 
one of these residues. The van der Waals interactions with Leu100, Val106, 
Val179, Tyr181, Cys190, Trp229, Leu234, and Tyr318 are also important in 
stabilizing NNRTIs in the pocket.5  
 Hydrogen bonding has especially proved to be important for efavirenz in 
maintaining its activity against the clinically relevant Y181C strain.113  Generally, 
a hydrogen bond requires a distance less than 3.2 Å and an angle of 120º ± 30º.  
The presence of a hydrogen bond adds ~2.5 kcal/mol to the binding energy, 
further stabilizing the NNRTI/pocket complex.114 
G. NNRTI-Induced Mutations 
 The first NNRTI-induced mutations discovered were the K103N 
(Lys103Asn103) and Y181C (Tyr181Cys181) strains.  These two mutations 
rendered RT resistant to all NNRTIs.  More specific mutations to individual 
inhibitors have been observed as well, for example HEPT, derivatives induce 
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K103N, V108I and Y181C mutations.115 Other mutations that are observed are 
G190E, L100I, V106A, L74V, V75I, L100I, E138K, and P236L.84 Although 
mutations make NNRTIs less attractive as therapeutic options, some of these 
compounds such as MKC-442 and efavirenz maintain good activity against 
mutant RT strains.84 Efavirenz maintains its activity levels in mutant strains 
V108I, E179D, Y181C as in wt HIV-1 RT.116  Severe resistance to NNRTIs in 
patients is only observed with double mutant strains; however, it is unclear how 
quickly these double mutations arise in vivo in patients under NNRTI therapy.  
Some of the most common double mutations are L100I/K103N, K101D/K103N, 
and K103N/Y181C.84 Mutant RT’s resistance to NNRTIs varies from one inhibitor 
to another.  In other words, some mutations may cause little effect on one 
inhibitor but render others completely inactive.  Table 1 shows resistance 
mutations that appear in patients taking NNRTIs as part of there HIV therapy.5  
Each of these mutations elicit a different reaction from the three FDA-approved 
NNRTIs. 5 Interestingly, RT’s resistance profile to NNRTIs differs completely from 
resistance to NRTIs.  All NNRTI mutations occur in the NNIBP pocket, while 
NRTIs mutations occur all over the RT enzyme, and strains resistant to NNRTIs 
maintain their activity against NRTIs and vice versa.5 This further stresses the 
importance of combination therapy. 
H. Sultams: A novel class of NNRITs 
Gussion and co-workers based their molecular modeling study on a low-
resolution (2.9 Å) crystal structure to generate an all-atom molecular model of th  
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Table 1.  Resistance mutations in patients treated with nevirapine(NEV), 
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NNIBP.  A pocket was generated from the reverse transctriptase crystal Cα 
coordinates.117   
This was followed by docking experiments of nevirapine and a few other 
analogues in order to identify elements of a pharmacaphore.  Following the 
identification of key functional groups in the pharmacaphore, a search on the NCI 
database of over 200,000 compounds produced 300 hits.  The search was then 
modified to give 33 compounds including nevirapine and NSC119833 (Figure 5). 
Further NCI database searches and 3D QSAR (quantitative structure–
activity relationship) studies paired with biological testing of the hit compounds 
led to the identification of NSC-108406 (Figure 5) with an IC50 ± 0.3 µM.  
Watanabe and co-workers were the first to report a synthetic route to sultam 
family of which of NSC-108406 is a member.118  Further work in our labs 
developed several synthetic routes to over 65 analogues of these sultams.(Work 





























Figure 6. General structure of sultams developed by the Baker group 
 
Sultams are derivatives of isothiazoles with an aromatic ring fused at C4 
and C5.  The sultams developed in our lab have the general formula shown in 
Figure 6 above.  The numbering begins with the sulfur atom. Both rings A and C 
are aromatic rings, while ring B is a heterocyclic ring.  The nitrogen is either 
secondary or tertiary depending on the nature of R1.  R2 in the meta-position on 
ring C varies in functionality.  In some derivatives ring A was substituted at C6, 
C7 or both.  The general synthetic route to these sultams is outlined in Scheme 1 
 
Scheme 1 











































The synthesis commences with the coupling of a substituted 
benzenesulfonylchloride to a primary alkyl amine. Lithiation at the ortho-position 
(termed ipso lithiation) is established using an alkyllithium reagent such as n-
butyllithium.  The lithiated species is then coupled to an aryl aldehyde (I-2), and 
then cyclization is accomplished by using a protic acid to afford a racemic 
mixture sultam I-4.  The racemate was then separated with chiral HPLC, and the 
enantiomers were submitted the NCI for anti-HIV studies.119  
Synthesis of sultams with halogen substitution required a modification to 
the original route.  The use of alkyllithium reagents for coupling is not suitable 
due to the presence of a halogen on ring A.  Lithium–halogen exchange can 
occur, which may lead to other side reactions and unwanted products.  Halogen- 
subsitituted o-aminobenzophenone (2-1) undergoes diazotization using HONO.  
SO2 is then added in the presence of ionic copper to form the sulfonyl 
functionality.  Condensation of (2-2) leads to the cyclization of the isothiazole ring 
(2-3). Hydrogenation of the imine functionality, followed by alkylation gives the 
desired sultam (2-5) in a racemic mixture (Scheme 2). 
To synthesize sultams with substitutions on ring C, yet another synthetic 
route had to be devised (Scheme 3).  2,4-Dimethoxyphenyl-(4-methoxyphenyl) 
methylamine is condensed with benzenesulfonylchloride. The product is lithiated 
and coupled to an aryl aldehyde or ketone. The monoalkylated and dialkylated 
compounds are isolated, and both are cyclized using a strong protic acid to give 









































































































Another class of sultams is those with a CF3 group at C3.  The synthetic route 
leading to such compounds begins with the coupling of tert-butylamine with 
benzenesulfonyl chloride (4-2). Alkylation of the resulting sulfonamide (4-3) is 
afforded by treatment with sodium hydride and iodomethane. The resulting 
product is then lithiated and coupled to an aryl ketone.  Sulfuric acid catalyzed 
cyclization produces the desired  
Separation of these racemates was accomplished either by chiral HPLC 
using a Chiralcel OD column or by derivitization of these compounds into their 














































Biological studies of all of these compounds showed decreased activity 
when the A ring was substituted.  The preferred substitution on ring C was the 
meta-position.  In order to synthesize additional sultams with substituents on the 
meta-position of ring C, another synthetic route was devised.  In this route 
saccharin was used to install rings A and B.  It was coupled with an aryl Grignard 
reagent to give 3-aryl-1,2-benzisothiazole 1,1-dioxide.  The C=N imine bond was 
then reduced enantioselectively to give enantiomerically pure products.  
Methylation using Cs2CO3 and iodomethane gave the desired sultams (Scheme 
5). 
A report in C & E News suggested that rhodium can be used to give 
racemic mixtures in various amine reductions.155  Using 
pentamethylcyclopentadienyl as a ligand in place of the η6-arene ligands that 
were traditionally used in such complexes,121 especially in the Noyori ruthenium 































prepared a chiral Rh-Cp* complex. Pentamethylcylopentadienylrhodium chloride 
dimer {[Cp*RhCl2]2} was coupled to (1R,2R)-N-p-toluenesulfonyl)-1,2-
diphenylethylenediamine {(1R,2R)-TSDPEN} to afford the R,R-catalyst and 
(1S,2S)-TSDPEN was used to prepare the S,S-catalyst.  Although the catalyst is 
considered to possess three chiral centers, the metal and the two centers on the 
TSDPEN ligand, it will be refered to as S,S when the S,S-ligand is used and R,R 
when the R,R-ligand is employed.  The structure of the R,R-catalyst was 
confirmed with X-ray crystallography, and its activity was tested on a variety of 
compounds.  Although the resulting enantioslectivity is modest, simple 
recrystallization methods of these enantio-enriched mixtures afforded the pure 
enantiomers.   Polar solvents were preferred; however, dichloromethane was just 
as efficient and the enantioselctivity was not affected.  The most suitable proton 
source was found to be formic acid/triethylamine azeotrope.  Reactions failed 
when 2-propanol/triethylamine was used.  The substrate-to-catalyst ratio (S/C) is 
200:1, while the Noyori catalyst requires a ratio of 100:1.  Reactions times were 
short, and yields were very good.  The enantioselectivity of this catalyst proved to 
be interesting. Generally, the S,S-catalyst produced the R product and vice 
versa; however, this observation is greatly affected by the nature of the 
substrate.  The bulkier groups such as the sultams with an aromatic C ring 
followed this phenomenon, and the smaller compounds such as sultams with 
alkyl groups in place of ring C gave the opposite results.122  It is worth noting that 
this catalyst exhibited very good stability, and was not hygroscopic or sensitive to 
 50 
air as many similar complexes are.   It also remained active at low temperatures, 
and higher temperatures did not seem to affect its enantioselectivity or activity.   
With the short synthetic route using saccharin, and the enantioselective 
catalyst at hand, we have designed and prepared new sultams with potential 




















II. Statement of the Problem 
 AIDS is currently the largest worldwide epidemic known in this century.  In 
an effort to join the many medicinal chemists in their battle against AIDS, we plan 
to use computer-aided docking experiments to design new sultams that will be 
active against wild-type reverse transcriptase (wt RT), as well as mutant RT, in 
particular the Y181C RT strain. Using RT crystal structure coordinates, the target 
sultams will be docked into the allosteric pocket of RT, and flexible docking 
(FlexiDock) experiments performed, using genetic algorithms to find the lowest 
energy conformation.  The results will be analyzed for distances between the 
ligand and key residues and hydrogen bonding sites.  While the calculated 
energies produced by FlexiDock in the SYBYL program are not real, they will 
serve as relative references to compare different fits.  A synthetic route will then 
be designed leading to the synthesis of these compounds.  From the modeling 
studies a set of compounds based on our 2,3-dihydro-3-(m-methylphenyl)-1,2-
benzisothiazole 1,1-dioxide and Merck’s efavirenz will be examined.  The best 
candidates structures will then be synthesized for evaluation.   
In the course of this work, we will collaborate with Professor John Turner 
and his student Megan Bragg on some NMR studies of the rhodium catalyst to 
identify the catalytic cycle. While Turner and co-workers will study the catalytic 
cycle through variable-temperature NMR studies, as well as some 2D 
experiments, we will attempt to further support their findings through molecular 
modeling studies.  The same principles of docking a substrate into an enzyme 
will be used. Various sultams will be docked into the catalyst. The complex will 
 52 
then be minimized and analysis of bond lengths and angles used to predict 























III. Results and Discussion 
A. Modeling 
1. The Tripos Force Field 
The four major components in the energy expression of the Tripos force field are 
the following:123-125   
(a) Stretching energy expression: the energy of a bond stretched or 
compressed from its original bond length. 
Estr = Σ Estr (1/2)kid (di−di0)2 
di = the length of the ith bond (Å) 
di
0 = equilibrium length of the ith bond (Å) 
ki
d = Bond stretching of force constant (kcal/(mol)(Å)2) 
(b) Angle-bending energy term: the energy from bending bond angles out 
of their natural values.  
Ebend = Σ Ebend (1/2) kiθ(θi−θi0)2 
θI = angle between two adjacent bonds 
θi0 = the equilibrium value of the θ 
ki
θ = angle force constant (kcal/(mol)(º)2) 
(c) Out-of-plane bending energy term: energy of bending planar atoms out 
of their plane.  
Eoop= Σ Eoop (1/2)kioop di2 
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di = distance between the center atom and the plane of its substituents.  
Ki
oop = the force constant for out of plane bending (kcal/(mol)(º)2 
(d) Torsional energy term: energy due to twisting around bonds.  
Etors = (1/2) Vi
ω[1+Sicos(|ni|⋅ωi)] 
Vi
ω= Torsional barrier (kcal/mol) 
Si = +1 minimum energy when staggered, −1 minimum energy when 
eclipsed 
ni = Periodicity 
ωI = torsion angle 
(e) van der Waals energy term: energy resulting from van der Waals 
interactions.  
Evdw = Σi=1 Σi>j Eij[(1.0/aij12)-(2.0/aij6)] 
Eij
 = van der Waals energy constant (kcal/mol)= (EiEj)
1/2 
aij = rij /(Ri + Rj)  
rij = distance between atoms i and j (Å) 
Ri = van der waals radius for the atom I (Å) 
The Tripos energy expression also contains optional terms such as energy 
from electrostatic interactions and energies from distant, angle and torsional 
constraints as well as a multifit energy term associated with multifits.  These 
expressions are only used when information about them is specified.  In the 
FlexiDock modeling studies described here and in the simple minimizations done 
on the sultams, no constraints were defined prior to the calculations; therefore, 
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these energy terms were not used in these calculations.  However, distance and 
angle constraints were used in the rhodium catalyst molecular modeling studies 
so some of these terms were automatically incorporated into the calculations.  It 
is important to keep in mind that any energy produced by a force field is not real, 
meaning it holds no physical value for individual conformations.  Energy values 
are used as points of reference to compare different conformations for a given 
molecule as well as difference among a set of similar molecules.  
The Tripos force field was used in its default parameters for all 
inhibitor/protein docking experiments.  For the rhodium catalyst calculations 
parameters for the rhodium metal center were added from the SYBYL metal 
database provided to all users.  
2. Charges 
 All small-molecule charges were calculated using the Gasteiger-Hückel 
method, which is a combination of two calculations.  The  π charge is assumed to 
be delocalized on all π atoms and calculated first using the Hückel method,126 
and then the σ charge is calculated using methodology outlined by Gasteiger and 
Marsili.127, 128 
 All protein charges were calculated using the Pullman and Berthod 
method, which is a combination of two methods, the Del Re method for σ charge 
calculation and the Hückel method for the π charge calculation.129, 130 
3. FlexiDock  
 FlexiDock is a docking program that utilizes crystal structure coordinates 
of known protein/inhibitor complexes.  The protein atoms are fixed coordinates in 
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space, while the ligand is mobile, i.e., rotation and translation of the ligand in 
space can be applied.  The protein residue side chains can be designated as 
flexible.  To achieve faster calculation times, only single non-ring bonds and 
amide bonds were allowed to flex (rotate). FlexiDock uses the Tripos force field 
(ff) to calculate energies of the different conformations generated by the genetic 
algorithm.  The default parameters between the two force fields are essentially 
the same; however, a few differences are present and they are summarized in 
Table 2 below.  
FlexiDock uses a steady-state genetic algorithm to generate, propagate 
and reproduce these genes.  Genetic algorithms are global optimizers that 
employ terminology and methodology from Mendelevian hereditary practices and 
Darwinian evolutionary theories in which the most fit members of a population 
are allowed to propagate into future generations.   
 
Table 2. Default Settings in FlexiDock and Tripos Force Field (from 
SYBYL FlexiDock Manual). 
Default Condition FlexiDock Tripos Force Field 
Hydrogen van der Waals 
radius 
1.0 Å 1.5 Å 
Hydrogen van der Waals 
Є  
0.03 0.042 
van der Waals distance 
cut off 




The algorithm begins with the formation of the initial population of 
chromosomes. A chromosome is a set of possible torsional, translational, and 
rotational positions a flexible bond might have. The number of genes on each 
chromosome depends on the number of rotatable bonds specified.  The 
chromosomes are then evaluated for energy using the the Tripos ff.  The best fit 
members of a population are then allowed to mutate or cross over.  The new 
generation is then evaluated again for energy values and so on and so forth.131  
The purpose of FlexiDock calculations is to explore the diverse solution space 
available for a specific problem.  FlexiDock monitors this diversity by monitoring 
the percent of gene convergence.  When 95% of the genes have converged, the 
calculation terminates, and the best twenty solutions are placed in a molecular 
database.  The number of generations used in a FlexiDock run depends on the 
number of flexible bonds designated by the user.  A more flexible ligand/protein 
complex requires a larger number of generations.  It is agreed that a minimum of 
500 to 1000 generations per gene are required to produce reasonable results.131  
A gene is the total number of flexible bonds in the ligand and the protein plus six. 
The default setting for FlexiDock is 3000 generations.  This value assumes there 
are no flexible bonds in the ligand or protein; therefore: 
(0 + 6) (500)= 3000 
In the FlexiDock experiments reported here the average number of bonds 
being flexed in both protein and ligand were around 50 bonds.  This means a 
minimum of 28,000–56,000 generations are needed to produce some results.  
This of course is a minimum value and a higher number of generations is 
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acceptable.  To allow a larger solution set to be discovered the maximum number 
generations was 130,000.  Each complex was minimized at least three times at 
varying seed numbers. This allows FlexiDock to explore a wider range in the 
solution space.  Each run gave 20 solutions, and all 60 solutions for each of 
these runs were evaluated quantitatively and qualitatively.  A hydrogen-bond site 
was not specified in these studies. Distances and angles between potential 
hydrogen donors and acceptors were evaluated.114 Based on these results, 
hydrogen bonding was predicted between the ligand and certain residues in the 
pocket.  
4. Preparing the Protein 
 Two major FlexiDock studies were prepared using wt RT and Y181C RT bound 
to efavirenz (pdb code 1ikw, 1jkh).132, 133  The crystal structures were obtained from the 
protein databases.  Efavirenz was extracted and deleted from the crystal structure.  
Hydrogens were added at random orientations, and Pullman charges were calculated for 
each protein.  A minimization was performed where the protein is treated as an aggregate 
or rigid structure and the hydrogens are considered flexible.  This was necessary to 
optimize the position of the added hydrogens.  Minimizations on the protein crystal 
structures were attempted; however, these studies did not yield any major differences in 
the orientation of the protein backbone. 
5. Defining the pocket 
 The non-nucleoside  inhibitor binding pocket (NNIBP) was defined based 
on available biochemical and molecular modeling data.31, 88, 108, 109, 134-136  
Hydrophobic interactions require a distance between the ligand and the residue 
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of 4 Å.114  Weaker binding interactions do occur at distances larger than 5 Å; 
however, any residue that is more than 10 Å away is not considered for binding.  
Such residues may be important for binding pocket formation or structural 
stabilization but not direct ligand–residue interactions. The pocket was defined as 
a sphere with a radius of 10 Å and the inhibitor at its center.  Manual inspection 
of the residues included in this sphere showed that all the key residues that form 
the NNIBP are present (see The non-nucleoside reverse transcriptase binding 
pocket section in the Introduction).   
6. Preparing the sultams  
 All sultams were sketched using the Sketch Molecule menu in SYBYL.  
Hydrogens were then added and Gasteiger–Hückel charges were calculated.  A 
quick minimization was then employed to minimize the adjust bond lengths and 
angles that may have been distorted during the sketching process.  
7. Docking the sultams 
 In docking experiments it is very helpful to have a starting position that the 
inhibitor can be placed in.  Efavirenz coordinates in the crystal structure were 
used to position the sultam inhibitor. The sultam was superimposed on top of 
efavirenz while it was still in the pocket and a three-atom fit was performed.  
Efavirenz was then deleted from the sequence, and the sultam merged into the 
enzyme.  This technique provides a better pre-positioning of the inhibitor and 
eliminates the cumbersome process of manually docking inhibitors into the 
pocket.  RMS values for the sultam/efavirens fit are reported in Table 3.  
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methyl-1,2-benzisohtiazole 1,1-dioxide  
0.31 
8. Preparing the FlexiDock File 
 The FlexiDock file is prepared by following a checklist provided by the 
FlexiDock menu: 
(a) Define pocket: The pocket is defined as the NNIBP previously 
specified plus 1 Å around it.  
(b) Extract ligand: Ligand is extracted and deleted from the protein 
sequence. This is done to allow each of these structures to be 
prepared separately. 
(c) Remove water molecules: FlexiDock removes all water molecules that 
belong to the set {WATER}. These water molecules were generated 
when the pdb files were read in from the protein database.  
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(d) Check atom types: This provides an option to modify any atom types 
that may have been improperly downloaded from the pdb file.  This 
was particularly common in previous SYBYL versions; however, the 
current version SYBYL7.2 has less of a problem.   
(e) Add hydrogens:  Since hydrogens were previously added on both the 
protein and ligand, no more hydrogens were added at this stage.  
(f) Add charges: the charges for the protein and the sultam have been 
individually calculated so the charges do not need to be reloaded again 
(g) Rotatable bonds: For the 3-(alkylethynyl)-2,3-dihydro-2-methyl-1,2-
benzisotiazole 1,1-dioxide (alkylethynyl sultam series), the N-methyl 
bond was allowed to rotate.  Flexible Residues: Lys101, Lys103, 
Tyr181or Cys181 (for Y181C mutant strain), Tyr183, Tyr188 (Cys188 
for Y188C), Trp229, Tyr318 were all chosen to have flexible side 
chains.  (See below for a discussion on the reasoning behind choosing 
these ligands).   
(h) Specify hydrogen-bond sites:  No hydrogen-bonding sites were pre-
specified in these studies.  The ligands were allowed to flex in the 
pocket without any H–bond constraints.  Then using distances and 
angles between the ligands and hydrogen-bonding residues, we 
predicted the presence of a hydrogen bond. 
(i) Pre-position ligand in the pocket: Since the sultam was fitted to the 
efavirenz coordinates in the RT pocket, it was not necessary to alter 
the ligand’s position any further.  
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(j) Name file: Create a name for the FlexiDock File 
(k) Write output file: this creates the FlexiDock file with the name specified 
in the previous step 
(l) FlexiDock it: this begins the flexidock calculation. 
Once the FlexiDock run is started, a random seed number is generated.  
All random seed numbers were noted.  As mentioned earlier the number of 
generations used was 130,000 generations in each of the runs.  Once FlexiDock 
was done, a set of twenty solutions are placed in a molecular database along 
with their energies.  
9. FlexiDock Studies 
 The residues chosen for flexing are mentioned above.  Each of these 
residues plays a key role in inhibitor binding.  Lys101 forms hydrogen bonds with 
wt RT.  Lys103 is part of the lysine triad Lys101–Lys103 (wing 1) and its 
orientation positions Lys101 for hydrogen bonding with the bound inhibitor.  It is 
also involved in pocket formation.  In the Lys103Asp103 (K103N) mutant strain 
efavirenz looses a good percentage of its activity because Lys101’s orientation is 
distorted and no hydrogen bond is formed.137, 138  Tyr181, Tyr188 and Trp229 
form the hydrophobic region of the pocket also known as the wing 2 region.5, 85, 
104 A number of π–π hydrophobic interactions form the basis of NNRTI binding to 
RT. Most inhibitors rely on the three main aromatic ring-stacking interactions; 
parallel (strong), staggered (medium) and T-shaped interactions (weak).    
Tyr181Cys181 is the most frequently occurring mutation observed in 
HIV patients receiving NNRTIs as part of their regimen.  Trp229 is the only 
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conserved amino acid across all HIV-1 reverse transcriptase strains in wt RT as 
well as Y181C RT.  Tyr318 is part of the wing 1 region, which is mostly 
comprised of non-aromatic residues such as the lysine triad.  Analysis of the 
observed distances between efavirenz and Tyr318 in wt RT and Y181C RT 
suggests that this residue increases in importance as wing 1 loses some of its 
hydrophobic character in Y181C.  
In order to keep calculation times within reason, the aforementioned 
residues were chosen to be the focus of the docking experiments.   The NNRTI 
binding pocket formation and binding process is a flexible and complex process.  
As these residues open up to form the binding pocket, they cause both local and 
global movement in the enzyme leading to inhibition of activity.   The FlexiDock 
studies reported here are localized studies and do not take into consideration the 
global effects on the overall protein conformation.  The sultams shown in Figure 
7 are considered to be structurally related to efavirenz.  Analyses of the docking 
results were done in comparison to efavirenz and its position in the NNIBP 
pocket.   Table 4 reports the distances and hydrogen-bond angles for efavirenz in 
(a) wt and in (b) Y181C RT.  
In binding studies a hydrophobic interaction is considered strong if the 
distance between the ligand and residue is less than 4 Å.  A distance between 4 
and 5 Å is thought to cause a moderate binding interactions, and anything larger 
than 5 Å is classified as a weak binding interaction.114  The FlexiDock cut off for 
van der Waals interaction is 16.5 Å; however, any distance greater than 10 Å will 




































































Table 4. (a) Distances and H-bond angle in the efavirenz/wt RT complex. (b) 
Distances and H-bond angle in the efavirenz/Y181C RT complex 
a. 
Efavirenz Residue in wt RT Distance 
(Å) 
Angle of H-bond if 
present (º) 
C=O Lys101 2.06 98.55º 
Cyclopropyl Tyr181 2.544  
 Tyr183 7.23  
 Tyr188 5.96  
 Trp229 4.49  
Aromatic ring Tyr318 5.84  
b. 




Angle of H-bond if 
present (º) 
C=O Lys101 2.31 97.76 
Cyclopropyl Cys181 —  
 Tyr183 7.26  
 Tyr188 3.99  
 Trp229 4.04  








Efavirenz forms a hydrogen bond in both the wt and Y181C RT with  
distances between the amide carbonyl in efavirenz and Lys101 at 2.06 Å and 
2.31 Å for wt and Y181C, respectively, with angles of around 98º for both.  Both 
angle and distance values are within what is needed for hydrogen bonding to 
occur in biological systems.114  Efavirenz is known to cause selection for Y181C 
mutation.  This is greatly supported by the significantly small distance, 2.54 Å, 
between the cyclopropyl group and Tyr181 in wt RT.  In wt RT the cyclopropyl 
ring is almost 6 Å away from the Tyr188, but this distance is decreased by 2 Å in 
Y181C.   
This occurs to compensate for the loss of the major hydrophobic 
interaction at Tyr181Cys181.  It is also worth noting that the cyclopropyl group 
becomes almost equidistant from both Tyr188 and Trp229 at 4 Å.  The aromatic 
ring in efavirenz is 6 Å away from Tyr318, and it is positioned in a T-shaped 
orientation towards the ring.  It could be hypothesized that the weakest type of π–
π interaction, the T-shaped interaction, is occurring here.  In Y181C the aromatic 
ring is closer to Tyr318 by 0.8 Å; however, its orientation does not change. Figure 
8 shows the positions of efavirenz in both wt RT and Y181C Rt.  
Tables 5–7 display the distances and hydrogen-bond angles (when 
hydrogen bonding is present) calculated by FlexiDock for 2-(alkylethynyl)-2,3-
dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide (the alkyethynyl sultam series, 
compounds 9–11). The Flexidock calculations predict a hydrogen bond between 
the sulfonyl group of cyclopropylethynyl sultam (9) and Lys101.  The distance 












Figure 8.  Efavirenz in wt RT (left) and Y181C (right). 
 






















Residue in wt RT Distance 
(Å) 
Angle of H-bond if 
present (º) 
SO2 Lys101 2.10 115 
Cyclopropyl Tyr181 4.20  
 Tyr183 7.85   
 Tyr188 5.6   
 Trp229 4.54   





Residue in Y181C Distance 
(Å) 
Angle of H-bond if 
present (º) 
SO2 Lys101 2.19  119.06 
Cyclopropyl Cys181 —  
 Tyr183 7.86  
 Tyr188 4.32  
 Trp229 5.24  













Residue in wt RT Distance 
(Å) 
Angle of H-bond if 
present (º) 
SO2 Lys101 3.00  — 
tert-Butyl Tyr181 5.09  
 Tyr183 7.88  
 Tyr188 4.3  
 Trp229 4.55  





Residue in Y181C Distance 
(Å) 
Angle of H-bond if 
present (º) 
SO2 Lys101 2.13 127 
tert-Butyl Cys181 –  
 Tyr183 7.19  
 Tyr188 4.19  
 Trp229 4.75  













Residue in wt RT Distance 
(Å) 
Angle of H-bond if 
present (º) 
SO2 Lys101 4.27 — 
Cyclobutyl Tyr181 4.61  
 Tyr183 7.54  
 Tyr188 4.60  
 Trp229 4.01  




Residue in Y181C Distance 
(Å) 
Angle of H-bond if 
present (º) 
SO2 Lys101 2.31 124 
Cyclobutyl Cys81 —  
 Tyr183 7.70  
 Tyr188 4.41  
 Trp229 4.87  








For the tert-butylethynyl sultam (10), no hydrogen bond is predicted.  The 
distance observed is 3 Å,. According to Mager and co-workers distances greater 
than 2 Å greatly weaken hydrogen bonding.114  It is difficult to definitively 
conclude whether the tert-butylethynyl sultam (10) forms a hydrogen bond with 
Lys101.  The cyclobutylethynyl sultam (11) is 4.27 Å away from Lys101. A large 
distance such as this one suggests that no hydrogen bond is formed.  In wt RT 
all three alkyl groups (cyclopropyl (9), tert-butyl (10), and cyclobutyl (11)) are 
between 4 Å and 5 Å away from Tyr181 which is at least 2 Å greater than the 
distance observed for efavirenz in the pocket.  The distances from Tyr188 vary 
from one sultam to the other.  The cyclopropylethynyl sultam (9) has the largest 
distance of all three inhibitors at 5.6 Å, while tert-butylethynyl sultam (10) and 
cyclobutylethynyl sultam (11) have similar distances ranging from 4.3–4.6 Å , 
suggesting hydrophobic interactions with this particular residue for both 
inhibitors.  All three inhibitors show a smaller distance between their alkyl groups 
and Tyr188 than that observed in the efavirenz/wt RT crystal structure.  All three 
inhibitors are more than 5 Å away from Tyr183, which is a result similar to that 
observed in the efavirenz/wt RT complex.  For the conserved Trp229 
cyclopropylethynyl- (9) and tert-butylethynyl (10) sultams are positioned at 4.5 Å 
from this residue. Efavirenz is also around 4.5 Å.  
Perhaps the most important observation for all three inhibitors in wt RT is 
that none of them favor a hydrophobic residue as is observed in the efavirenz 
pocket.  It would be interesting to see whether or not these molecules induce 
aspecific mutation in wt RT much like efavirenz.   A visual inspection of aromatic 
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ring A finds all three inhibitors in a staggered orientation with Tyr318 and the 
distance calculated for all three is around 6 Å.  This could be a staggered π–π  
weak interaction, but it is very hard to determine that.  Figure 9 depicts all three 
alktylethynyl sultam in wt RT superimposed over efavirenz.  Figure 10 shows 
each docked in the pocket separately.  The white ligand in both figures is 
efavirenz. Cyclopropylethynyl is red, ter-butylethynyl is blue and cyclbutylethynyl 
is green.  Hydrogen bonds are depicted with red or yellow dashed lines.   
 
Figure 9. All alkyethynyl sultams docked into wt RT and superimposed on the 
Efavirenz wt RT pocket. Red (cyclopropylethynyl), blue (tert-butylethynyl), green 
(cyclobutylethynyl), white (efavirenz). The yellow dotted line H-bond between 
Lys101 and cyclopropylethynyl sultam and red dotted line represents a hydrogen 
bond between Lys101 and efavirenz.. 
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Figure 10.  The alkylethynyl sultam series shown with efavirenz in wt RT and 














A noticeable change is that all three sultams lie closer to Lys101, and a 
hydrogen bond is predicted to form for all three of them.  The most dramatic 
decrease in distance between the SO2 group and the Lys101 NH hydrogen is 
observed in the cyclobutylehthynyl sultam where a decrease of 1.86 Å is 
reported.   The calculated distances between SO2 
 and NH Lys101 range 
between 2.13 Å and 2.31 Å, and  the observed H-bond length in efavirenz Y181C 
crystal structure is 2.31 Å.  Two sultams have shorter hydrogen-bond lengths 
than those observed in the crystal structure of the efavirenz/Y181C RT complex.  
The angles for these bonds range between 119º and 127º. All angles are within 
the range observed for hydrogen bonding in biological systems (Figure 11).114  
Visually these sultams appear to bind more similarly to efavirenz in this mutant 
pocket than in the wt pocket.  Refer to Figures 11 and 12 for images of the 
docked sultams in Y181C superimposed on the efavirenz pocket.  
Due to some synthetic challenges, of the three molecules discussed 
above, we were only able to synthesize 3-(tert-butylethynyl)-2,3-dihydro-2-
methyl-1,2-benzisothiazole 1,1-dioxide (10) as a racemic mixture.   However, five 
other compounds that were produced as side products or unexpected products 
were isolated.  The 3-(cycloalkyl)-2,3-dihydro-2-methyl 1,2 benzisothiazole 1,1-
dioxides (cycloalkylethyl sultams, compounds 12 and 13) and the 3,3-(dialkyl)-
2,3-dihydro-2-methyl-12-benzisothiazole 1,1-dioxide (dialkylated sultams, 
compounds 15, 16 and 17).   Although these two groups of compounds were not 




Figure 11. (A) 3-(cycloalkyethynyl) sultam in Y181C RT/efavirenz pocket. 







Figure 12. (A) cyclopropylethynyl  sultam in Y181C RT, (B) tert-butylethynyl 













 Both 3-(cycloalkylethyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-
dioxides (12 and 13) were docked into wt RT and Y181C following the same 
protocol outlined earlier with at least three separte experiments at different 
random seed numbers and 130,000 generations. Each study gave twenty 
possible solutions. The lowest energy conformation was then evaluated for 
distances, hydrogen-bond lengths and hydrogen-bond angles.  In the wt RT both 
cycloalkylethyl sultams produced flipped conformations (Figure 13).  Both the 
cyclopropyl and cyclopbutyl groups are in the wing 1 region.  Figure 14 shows 
these two sultams superimposed with the efavirenz pocket without any amino 
acid residues.  It is also important to note the orientation of the ethyl group which 
appears to be extremely strained.  To quantitatively get a grasp on the energy of 
these conformations, the lowest energies of both studies were compared to the 
lowest energies from the Y181C docking studies.  For 12, the lowest energy in 
the wt RT pocket shown above is −260 kcal/mol while the lowest energy for the 
Y181C pocket is −219 kcal/mol (41 kcal/mol decrease in energy).  In the Y181C 
the binding conformation of this sultam is similar to that observed in the efavirenz 
pocket.  It is important to stress that these energies have no real physical value 
but serve as a point of reference in comparing the different binding 
conformations.  It is necessary here to rely on the energy values rather than the 
distances and angles because these two conformations are completely different, 



















as efavirenz.  For the cyclobutylethyl sultam 13, the lowest energy conformation 
observed in wt RT is −244 kcal/mol, while it is −212 kcal/mol for Y181C ( 32 
kcal/mol energy change).  Again the binding conformation of the cyclobutylethyl 
sultam 13 in Y181C mimicks that of efavirenz in Y181C and wt RT. Tables 8 and 
9 report distanced and angles observed for both sultams.  Figure 14 depicts them 
in the Y181C RT cavity superimposed onto the efavirenz/Y181C RT crystal 
structure.   
Both inhibitors are predicted to form hydrogen bonds with Lys101.  The 
calculated distance between the sulfonyl group and NH of Lys101 is 1.77 Å and 
1.74 Å  for cyclopropylethyl sultam (12) and cyclobutylethyl sutlam (13), 
respectively, (2.3 Å for efavirenz) with angles of 130.69º and 131.69º (Tables 8 
and 9).  Both inhibitors have distances that are no more than 5 Å away from 
Tyr188,Tyr183, and Trp229.  The cyclopropyl and cylobutyl rings are closest to 
Tyr188 with a distance of approximately 4.10 Å for both.  The binding 
conformations of both inhibitors are very similar to that of efavirenz in the pocket 
(Figure 14).  Of all the inhibitors docked so far, these compounds make the most 
interesting candidates for biological evaluation.  The energies of these two 
inhibitors in this particular pocket are significanlty lower than the calculated 
energies of the other sultams discussed above.  The alkylethynyl sultam series 
lowest binding energies range between −260.01 kcal/mol and −269.65 kcal/mol, 
while the lowest binding energies for the cycloalkylethyl sultam series are less 
than −220 kcal/mol.  Table 10 lists the lowest binding energies in both wt RT and 
Y181C.  
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Table 8.   Distances and hydrogen-bond angles between cyclopropylethyl 








Angle of H-bond if 
present (º) 
SO2 Lys101 1.77 130.69 
Cyclopropyl Cys81 —  
 Tyr183 7.74  
 Tyr188 4.10  
 Trp229 4.66  
Aromatic ring Tyr318 4.80  
 
 
Table 9. Distances and hydrogen-bond angles between cyclobutylethyl sutlam 








Angle of H-bond if 
present (º) 
SO2 Lys101 1.74 131.69 
Cyclobutyl Cys81 —  
 Tyr183 7.49  
 Tyr188 4.09  
 Trp229 4.51  









Figure 14. (A) Cyclopropylethyl sultam (magenta) and cyclobutylethyl sultam 
(yellow) in Y181C RT with efavirenz (white).  (B) All three inhibitors in the pocket 







Table 10. .  Calculted energies in both wt RT and Y181C RT 
 




































The isolation of  3,3-bis(allylethynyl)-2,3-dihydro-2-methyl-1,2-
benzisothiazole 1,1-dioxides (bisalkylated sultams compounds 15–17) as side 
products from our reactions (see synthetic discussion section) prompted docking 
experiments into wt RT and Y181C.  The three compounds proved to be too 
large for the wt RT.  The docking experiments were tried several times, and the 
lowest binding conformation was either placed outside of the pocket or in 
conformations that made no contacts with the key residues being inspected.  As 
mentioned earlier, although NNRTIs are strucurally diverse, they all make key 
contacts with specific pocket residues. These contacts were not observed in 
these studies.  
Compounds 15–17 were docked  into Y181C RT using the 
efavirenz/Y181C RT crystal coordinates.  The binding conformations of all three 
compounds did not adopt a similar orientation to that off efavirenz. However, 
bis(cyclopropylethynyl) sultam (17) and bis(tert-butylethynyl ) sultam (16) 
exhibited interesting binding interactions with certain pocket residues. Tables 11 
and 12 report the calculated distances.  The sulfonyl group for 
bis(cylopropylethynyl) sultam (17) is no longer oritented toward Lys101, but 
instead points directly at the SH moeity of Cys181.  The distance measured is 
3.96 Å.  The bis-tert-butylethynyl (18) sultam has its SO2 group also oriented in a 
similar fashion with a shorter distance of 2.37 Å.   SYBYL does not predict a 
hydrogen bond between the ligand SO2 and Cys181; however, these docking 
experiments were performed at least three times, and sixty possible solutions 
were inspected.  The SO2 position was always reoriented towards Cys181.  This  
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Table 11. Distances between dicyclopropylethynyl sultam and key 
residues in Y181C RT 
 
Ligand Residue Distance (Å) 
SO2 Cys181 3.96 
Cyclopropyl (A) Tyr183 5.72 
 Tyr188 5.77 
 Trp229 4.3 
Cyclopropyl (B) Tyr318 3.75 
 
Table 12.  Distances between the dyclopropylethynyl sultam and key residues in 
Y181C.  
 
Ligand Residue Distance (Å) 
SO2 Cys181 2.37 
tert-butyl (A) Tyr183 7.32 
 Tyr188 5.006 
 Trp229 4.42 






indicates that  some sort of electrostatic interaction is ocurring, most probably a 
hydrogen bond.  The second most noticeable interaction is the position of one of 
the cyclopropyl groups and tert-butyl groups.  Both are oriented directly toward 
the aromatic ring of Tyr318 and the calculated distances are 3.75 Å and 3.26 for 
cyclopropyl (15) and tert-butyl (16), respectively.  Tyr183 remains at least 5 Å 
away from each ligand.  Trp229 seems to also make contact with one cyclopropyl 
group and one tert-butyl group at a distance less than 4.5 Å.   Whether these 
distances lead to binding and activity cannot be concluded from these results.  
Since these compounds do not adopt a similar orientation to efavirenz in this 
pocket, it is difficult to compare the observed crystal structure distances and the 
calculated distances of our compounds. And it is also difficult to predict acitivity.  
However, upon comparison of these structures with the nevirapine/Y181C RT 
crystal structure,  it was discovered that these bisalkylated sultams have similar 
binding conformations to that of nevirapine (Figure 15).  Nevirapine has very low 
activity against mutant RT strains, particularly those with mutations in the 





























Figure 15.  Dialkylated sultam 15 and 16 in Y181C/nevirapine pocket. (A) 
Dicyclopropyl (violet), di-tert-butyl (red) nevirapine (white) with all residues. (B) 





1. 3-(Alkylethynyl)-1,2-benzisothiazole 1,1-dioxide  
The original synthetic route leading to the ethynyl series followed a similar 
plan developed by Baker et al. to synthesize 3-(R)-aryl-2,3-dihydro-2-methyl-1,2-
benzisothiazole 1,1-dioxides (Scheme 5 ).119 Two equivalents of aryl magnesium 
chloride or bromide Grignard reagents were coupled  with one equivalent of 
saccharin to give the respective 3-(aryl)-1,2-benzisothizole 1,1-dioxides in good 
yield.119 Following the same logic, a synthetic route was outlined using 
alkynylithium reagents with saccharin to give the desired 3-(alkylethynyl)-1,2-
benzisothizole 1,1-dioxides using methodology developed by Abromovitch et al. 










The alkylehtynyllithium species is first generated by metal exchange with 



















1.1.5 equiv Cs2CO3/DMF or CH3CN/r.t/ 1 h









R = cyclopropyl, cyclobutyl or ter t-butyl
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temperature −78 ºC–(−40 ºC).  The saccharin is then added dropwise via a 
syringe. The reaction is warmed to room temperature overnight. It is then cooled 
to 0 ºC and quenched with saturated NH4Cl (aq).   It quickly became apparent 
that the desired 1,2-benzisothizole 1,1-dioxides were not being formed by this 
reaction.  
Examination of 1H NMR, 13CNMR and HRMS data suggests a 3,3-
bisalkylated product (Scheme 7).  The 1H NMR spectrum of compound 12 has an 
aromatic signal at 7.74–7.75 ppm that integrates to four protons. A multiplet at 
1.29–1.20 ppm belongs to the CH in the cyclopropyl group, but integrates to two 
protons. The multiplets between 0.81 and 0.68 ppm are signals for the 
cyclopropyl CH2 groups, and those integrate to six protons.  Furthermore, 
compound 12 has a signal at 5.0 ppm which disappears upon addition of D2O, 
confirming that this is an exchangeable proton, most probably the NH proton.  
Had this been the desired sulfonimine, an exchangeable proton should not be 
present nor should there be a 2:1 ratio between the alkyl and aromatic region.  
Moreover, the 13C NMR spectrum lacks the imine signal typically observed 
around 160 ppm, but it has a peak at 52  ppm.  DEPT experiments indicate that 
this signal belongs to a quaternary carbon.   
To further support the theory that this indeed was the 3,3-bisalkylated  
product, all three compounds were submitted to high-resolution mass 
spectrometry atmospheric pressure photoionization (HRMS-APPI).  The 
observed m/z came within either the third or fourth decimal place of the 
calculated mass for all three samples. HRMS-APPI is a gentle ionization method 
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that does not rely on acid/base reactions to create the molecular ion.  Instead, 
the sample is passed through a nebulizer where it is bombarded by a UV/vis light 
source.  A molecular ion radical is then formed by absorption of a photon and 
subsequent loss of an electron. 
Scheme 7 









These results were surprising, especially in that this methodology has 
been used in the synthesis of similar 1,2-benzisothiazole 1,1-dioxides, albeit in 
low yields.139, 140  Scheme 8 depicts a proposed mechanism for the bisalkylation 
reaction.  The first step is an acid–base reaction where the acidic N–H proton is 
abstracted to form intermediate 8-A.  Intermediate 8-A then abstracts from a 
proton source.  Considering that the reaction is performed under anhydrous 
conditions and an aprotic solvent, it is difficult to explain the origin of this proton.  












1.1.5 equiv Cs2CO3/DMF or CH3CN/r.t/ 1 h
2. 3 equiv MeI
15 R = cyclopropyl
16 R = cyclobutyl









12 R = cyclopropyl
13 R = cyclobutyl
14 R = ter t-butyl
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provides the proton source.  This forms intermediate 8-B. Attack by another 
equivalent of the alkylethynyllithium species affords intermediate 8-C.  The 
electron pair on the nitrogen then fold back to form imine (8-D) causing an [OH]− 
to leave.  Another equivalent of the lithium reagent then attacks the imine bond, 
and upon workup the bis-(alkylethynyl) product is formed.  Scheme 8 depicts a 
stepwise mechanism based on the synthetic results observed.  Whether 
intermediate 8-A does really exist or if the first two steps occur in a concerted 
fashion leading to intermediate 8-B remains unclear. What is obvious from the 
products isolated is an [OH]− must leave in some form.  
Other mechanistic pathways have been considered where the 
alkylethynyllithium species attacks the carbonyl first.  However saccharin is acidic 
with a pKa of ~2.0, and acetylenic protons have pKa of ~25.  This suggests that 
the first step has to be an acid–base reaction. Another possible mechanism is 
shown in Scheme 9.  Here the alkylethynyllithium abstracts a hydrogen from 
saccharine and forms the lithiated saccharine species 9-A.  Another equivalent of 
alkylethynyllithium then attacks the carbonyl to give intermediate 9-B.  The 
protonation of the nitrogen is accomplished by using saccharine which is already 
present in solution as the proton soruce.  The oxygen electrons then collapse to 
reform the carbonyl group and 9-E is formed.  Acidic workup gives the 
bisalkylated sultam.  
The saccharin is added dropwise to the alkylethynyllithium solution, so at 
any given moment in time there is an excess amount of lithium reagent relative to 
saccharin. We attempted to avoid this dialkylation by adding the lithium species 
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to the saccharin, but that only gave the same results with even lower yield due to 
the decomposition of the lithium species.   Maintaining a low temperature 
throughout the reaction and quenching at −78 ºC did not change the results.  The 
use of alkylethynylmagnesium bromide reagents was unsuccessful at varying 










































































It was clear at this point that a new approach is needed to accomplish the 
task at hand.  The new synthetic route shown below (Scheme 10) utilized 
methodology developed by Davis and co-workers.140  3-Ethoxy-1,2-
benzisothiazole 1,1-dioxide is prepared from 3-chloro-1,2-benzisothiazole 1,1-
dioxide. It is then coupled to the alkylethynyllithium species.  Davis and co-
workers reported that the success of this method varied depending on the lithium 






























































saccharin couplings, but in some cases either very low yields or no product 
formation was reported.140 This method was attempted several times, but even 




Considering that the chlorine would be a better leaving group than the 
ethoxide, a synthetic plan utilizing 3-chloro-1,2-benzisothiazole 1,1-dioxide 
directly was put together.  Scheme 11 represents the full synthetic route to the 
target molecules.  Preparation of 1 is accomplished by the molten reaction of 
phosphorus pentachloride (PCl5) at 180 ºC, then cooling to 100 ºC and applying 
vacuum to remove POCl3 that formed during the reaction.  Recrystallization from 
hot toluene provided 1 in 78% yield.  1H NMR and 13C NMR spectra were 
obtained and matched the expected signals.  No NMR data for this compound is 
available in the literature. The observed mp is 139–143 ºC, and the value 
reported in the literarture is 140–144 ºC.141   
This methodology was developed for the synthesis of 2,3-dihydro-3,3-
dimethyl-1,2-benzisothiazole 1,1-dioxides,142  but has not been reported as a 
route for the preparation of 3-alkyl-1,2-benzisothiazoles.  The coupling reaction 
between 3-chloro-1,2-benzisothiazole (1) and the alkylethynyllithium reagent 


















1.3 equiv. R LiX-78 C-r.t-reflux
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1,1-dioxide was dissolved in dry THF and added very slowly to the lithium 













Then the reaction was quenched with saturated NH4Cl (aq) at 0 ºC.  The major 
products isolated were 3,3-bisalkyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxides 
(compounds 12, 13, 14).  All structures were confirmed by 1H NMR and 13C NMR 
spectroscopy and HRMS-APPI analysis, and the results matched those of the 
products obtained from the saccharin route.  Once again the reaction was 
attempted at variable temperatures.  One equivalent of 3-chloro-1,2-
benzisothiazole 1,1-dioxide was added at −78 ºC, and the reaction was 



















1. 1 equiv n-BuLi, -78 oC-(-40) oC
2. 1.5 equiv
2 R = cyclopropyl
3 R = cyclobutyl
4 R = ter t-butyl
1.1.5 equiv Cs2CO3/DMF or CH3CN/r.t/ 1 h









5 R = cyclopropyl
7 R = cyclobutyl
8 R = tert-butyl
10 R = tert -butyl
11 R = cyclobutyl
1
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alkylating the chloro pseudosaccharine twice in a mechanism such as that shown 









The number of 3-chloro-1,2-benzisothiazole 1,1-dioxide equivalents was varied.  
Three reactions were run at the same time using 1.1, 1.3 and 1.5 equivalents (1) 
to one equivalent of alkylethynyllithium reagent.  The reaction temperatures were 
maintained at −78 ºC during and after the addition, and the addition rate was 
dropwise at a medium speed.  The bisalkylated product was once again the 
major product; however, the 2-(alkylethynyl)-1,2-benzisothiazole 1,1-dioxide was 
also observed.  The reaction was monitored by TLC during the addition, and a 
new higher migrating spot began to form towards the end of the addition period.  
1H and 13C NMR spectroscopy indicated that this newly observed product is the 
desired 3-(alkylethynyl)-1,2-benzisothiazole 1,1-dioxide.  The next goal was to 



























3-Chloro-1,2-benzisothiazole 1,1-dioxide was dissolved in THF, and it was 
poured directly onto the alkylethynyllithium reaction mixture.  The flask was 
refitted with a septum and a nitrogen line, and it was monitored by TLC for one 
hour.  It was then quenched with saturated NH4Cl at −78 ºC.  The dialkylated 
product formation was greatly diminished when 1.1 and 1.3 equivalents were 
used as observed by TLC. It formed in small amounts when 1.5 equivalents of 1 
were used for the cylopropylethynyl (2) and tert-butylethynyl (4) analogues, but it 
was never completely eliminated from the reaction mixture.  However, the 
dialkylated product formed for the cylobutylethyne analogue regardless of the 
number of equivalents used.  Although using this technique greatly improved the 
yields for these reactions, the overall % yields remained moderate for all three 
compounds (2, 3 and 4).  Davis and co-workers reported moderate to good yields 
depending on the alkyllithium species used.140  
2. 2,3-Dihydro-3-(alkylethynyl)-1,2-benzisothiazole s 1,1-dioxides 
The next step was the reduction of the imine bond using the rhodium 
catalyst (Figure 16) developed by Mao and Baker122, 143 who reported great 
success with this catalyst in the enantioselective synthesis of 3-(aryl)-2,3-
dihydro-1,2- benzisothiazole 1,1-dioxides.  According to Mao and Baker the R,R-
catalyst gave the S stereochemistry and vice versa.  However, they observed 
that this  
trend decreased and was completely reversed as the size of the C-3 group 









Figure 16.  Structure of ((R,R)-N-(p-tolunesulfonyl)-1,-2-
diphenylethylenediamine)-rhodium-(pentamethycycopentadienyl)-Cl ((R,R)-
[TSDPEN]RhCp*Cl). 
Initially methodology developed by Mao and Baker was used.  While the 
reaction conditions seemed to work, reaction times were 6 h.  Reduction of 
compound 4 into 8 proceeded smoothly with good yields (60%).   Reductions of 
3-(aryl)-1,2-benzisothiazole 1,1-dioxide  proceeded with much higher yields.  
During the purification process, it became apparent that the benzisothiazoles 
contained small amounts of the bisalkylethynyl products which may explain the 
lower yield in the desired product since our starting material was not 100% pure.  
Complete separation of these compounds was successful.   Reduction of 2 and 3 
into 5 and 7, respectively, (Scheme 13) was not successful.  The 1H NMR 
spectra of the new compounds have unexpected signals in its aliphatic region.  
The two new signals integrate to 2H each suggesting —CH2 groups.  The 
13C 
NMR spectrum lacked the alkyne signals observed in the other 1,2-








signals in the aliphatic region as well.  The observed m/z for compound 5 [M+H]+ 
is 238.0907 (234.0510) and for compound 7 250.969 (247.067) an increase of 
four units or four hydrogens.  All of these results help prove that the compounds 
obtained from this reduction are the 3-(cyclopropylethyl)- and 3-(cyclobutylethyl)-
1,2-benzisothiazole 1,1-dioxides.  To avoid the reduction of the alkyne moiety, 
variable reaction conditions were attempted.  The reaction was first monitored by 
low resolution EIMS.  Small aliquots of the reaction at 20 min, 30 min and 60 min 
were taken, and no trace of the desired compound was found. The isolated 
products after 30 minutes and up were that of the over-reduced compounds 6 or 







The active form of the catalyst is the Rh-hydride species.  The pre-catalyst 
shown in Figure 16 is converted to the active catalyst  by hydride transfer from 
the formate ion present in the azeotropic mixture onto the metal center with loss 
of a chlorine ion.  The catalyst was dissolved in a small amount of dry 




















S/C 200:1, HCOOH:Et3N (5:2)
r.t.
2 R = cyclopropyl
3 R= cyclobutyl
6 R = cyclopropyl
23 R = cyclobutyl
12 R = cyclopropyl
24 R = cyclobutyl
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dioxide gas bubbles were observed, as CO2 is released as the formate ion loses 
a hydride to the metal center to form the active complex.   The mixture was 
stirred for 10 min, and then a solution of compound 2 or 3 in dry dichloromethane 
and one equivilant of formate to substrate were added.  A color change from red 
to a dark brown color was observed within 15 min.  The reaction was quenched 
and purified, and only starting material was recovered. This procedure was 
repeated several times with varying reaction times (30, 60, 120 min).  The only 
product isolated, if any, was compound 6 or 23.  As mentioned above, the 
reaction was complete at approximately 2.5 h. Compounds 6 and 23 exhibited no 
optical activity. The reason for the reduction to the alkyl compound is not known 
at this time.  
3. 3-(Alkylethynyl)-2,3-dihydro-2-methyl-1,2-benzis othiazole 1,1-dioxide 
Methylation of compounds 6, 23 and 8 into compounds 12, 24, and 10, 
respectively, was carried out using Cs2CO3 as base and iodomethane as the 
methylating reagent in either N,N-dimethylformamide (DMF) or acetonitrile.  The 
reactions proceeded to completion at room temperature.  The synthetic route 
followed by Mao and Baker employed DMF as a solvent system due to the 
solubility of Cs2CO3 in DMF.  Cs2CO3 was found to be equally soluble in 
acetonitrile, and the reactions proceeded to completion.  The use of acetonitrile is 
more convenient because DMF is difficult to remove from the reaction mixture.  
 The progress of the reaction was monitored by TLC, and surprisingly two 
spots were observed.  Both spots ran closely to each other much like two 
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diastereomers of the same compound.  Both spots were collected together, and 
their 1H NMR and 13C NMR spectra were obtained.  The 1H NMR spectrum of 10  
contained two H3 and two N-CH3 signals.  HRMS-APPI for 2,3-dihydro-2-methyl-
3-(tert-butylethynyl)-1,2-benzisothiazole 1,1-dioxide (10) observed only one m/z 
at 262.0933 (262.0902).  HRMS-APPI for 2,3-dihydro-2-methyl-3-
(cyclopropylethyl)-1,2-benzisothiazole 1,1-dioxide (12) and for 2,3-dihydro-2-
methyl-3-(cyclopropylethyl)-1,2-benzisothiazole 1,1-dioxide failed.  No other 
significant peaks were observed.  Apparently 3-alkyl-2-alkyl-1,2-benzisothiazoles 
do not easily ionize.  Variable light source intensities did not cause these 
compounds to ionize.  However, 1H NMR and 13C NMR spectra clearly indicate 
the expected structures.  Further analysis would be needed for these 
compounds.   
4. A complete analysis of 10 
Both components of compound 10 were successfully isolated. The fast- 
migrating spot is designated 10a, and the slower migrating spot is referred to as 
10b.  Recrystallization of these two spots was only successful for 10a.  When 
compound 10b was resdissolved for recrystallization, a TLC sample was taken, 
and two spots reappeared.  When the crystals of 10a were redisolved for 2D 
NOESY experiments, a 1D 1H NMR spectrm was obtained.  From this spectrum it 
was determined that the signal at 5.59 ppm is H3 for 10a, and the signal at 3.12 
ppm belongs to the N-methyl protons in 10a.  As the sample remained in 
solution, the other two signals reappeared, and TLC indicated the formation of 
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10b again.  2D NOESY experiments were run on the mixture.  A cross peak 
between the singlet at 5.99 ppm and the singlet at 3.12 is observed, but no cross 
peak is observed between the singlets at 6.13 ppm (H3 in 10b) and 3.21 ppm 
(CH3 in 10b).  These results confirm that the orientation of the methyl group on 
the nitrogen varies between 10a and 10b and that H3 in 10a is clearly within 5 Å 
or less from the methyl group on the nitrogen, while H3 in 10b is more than 5 Å 
away.  From these results one can hypothesize that 10a  and 10b are 
conformers of the same molecule.  HRMS-APPI analysis only show the m/z 
expected for 10.  Other sultams have been reported to exhibit such a phenomena 
where two conformers are in equilibrium in solution.144  To further support our 
hypothesis, variable-temperature 1H NMR experiments were carried out (Table 
13). Our attention was focused on the N-CH3 singlets at 2.38 ppm and 2.24 ppm.  
The two methyl group signals clearly show movement toward coalescence as the 
temperature rises.  At 300 K the ∆ ppm between the two signals is at 0.14 ppm. A 
gradual decrease in the difference between the two peaks and a slight 
broadening of the peaks was observed as the temperature increased.  The 
highest temperature reported here is 405 K.  Unfortunately, at 410 K, the probe 
temperature would not stabilize.  To avoid the risk of overheating the probe, the 
experiments was halted.  The exact coalescence point was not observed.  The 
results observed exhibit enough of a patern to conclude that the methyl signals 




Table 13.  VT 1H NMR experimental results 
Temperature (K) N-CH3
 (10a) N-CH3 (10b) ∆ (ppm) 
300 2.38 2.24 0.14 
315 2.45 2.33 0.12 
350 2.62 2.54 0.08 
365 2.70 2.63 0.07 
380 2.77 2.71 0.06 
390 2.81 2.77 0.04 
395 2.82 2.78 0.04 
400 2.82 2.79 0.03 
405 2.86 2.83 0.03 
 
5. 3,3-Bis-(alkylethynyl)-2,3-dihydro-2-methyl-1,2- benzisothiazole 1,1-
dioxide  
 Although the 3,3-bis-akylated compounds were not synthetic targets for 
this project, they were methylated as well.  They were also docked into reverse 
transcriptase and evaluated for potential anti-HIV activity.  The methylation 
reactions for compounds 12,13 and 14 afforded compounds 15,16 and 17, 
respectively, in very good yields (Scheme 4). NMR spectroscopy and HRMS-
APPI confirmed these structures.  
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C. Modeling of 3-(m-cyclopropylpheynyl)-2,3-dihydro -2-methyl-1,2-
benzisothiazole 1,1, dioxide (m-cyclopropylpheny su ltam 18) and 2,3-
dihydro-3-(isopropylfuranyl)-3-methyl-1,2-benzisoth iaozole 1,1-dioxide 
(isopropylfuranyl sultam 19) 
 Another series of compounds were docked into wt RT and Y181C (Figure 
17).  The structures were inspired by the original sultam NSC-108406.  Both of 
these sultams have first generation NNRTI structural features.  Both have two 
aromatic rings that form the π  and the extended π systems. Both have a 
substituted ring C on position-3 or the meta-position.  The unique feature of 19 is 
that the extended π system in ring C is a heterocyclic ring.  This compound was 
designed with Y181C RT in mind.  Since loss of activity in mutant RTs is 
attributed to loss of pocket hydrophobicity, and therefore loss of major binding 
interactions, it was hypothesized that a heterocyclic ring may be able to form a 
























The methyl group in NSC-108406 was substituted with a cyclopropyl 
group in the meta-position.   This was inspired by efavirenz and its high activity 
against wt RT and its sustained activity against mutant RT strains.  Compound 
18 was docked into the wt RT and Y181C.  Tables 14 presents FlexiDock results 
for 18 in wt RT.  In the wt RT pocket the distances observed are quite interesting.  
Each ring in the ligand makes close contacts with specific residues, and each 
residue is within 4–5 Å of one of these rings.  This ensures that all key residues 
are bound to a part of the ligand.  Whether this means this inhibitor will be more 
tightly bound to the pocket remains to be seen through biological activity studies.  
The cyclopropyl ring makes two close contacts with Tyr181 (3.94 Å) and Trp229 
(4.37).  Ring C, on the other hand, makes a close contact with Tyr188 (4.37 Å).  
All three residues are essential for NNRTI binding to wt RT.  Unfortunately 
SYBYL does not predict a hydrogen bond with Lys101 (3 Å).   Although this 
compound is not considered to be structurally related to efavirenz, its orientation 
was still compared to efavirenz in the pocket.  Visual inspection of docked 
models do not show much similarity between the binding conformations of the 
two compounds, but based on the measured distances of 18 and the observed 
distances of efavirenz/wt RT crystal structure, both cyclopropyl groups make very 






Table 14.  Presents the results for m-cyclopropylphenyl sultam (1) in wt RT. 
 
 
Ligand Residue Distance 
SO2 Lys101 3.39 
Cyclopropyl Tyr181 3.94 
 Tyr183 7.59 
 Tyr188 5.93 
 Trp229 4.35 
Ring C Tyr181 5.98 
 Tyr183 8.84 
 Tyr188 4.37 
 Trp229 5.55 


























Docking into Y181C provided the results reported in Table 15.  
Unfortunately no hydrogen bond was predicted for 18 with Lys101 (3.34 Å).  
Much like the alkylethynyl series, the cyclopropyl group makes a stronger contact 
with Tyr188 (3.78 Å) than in the wt pocket (5.18 Å). This is due to the loss of the 
large aromatic interaction with Tyr181 as it mutates to Cys181.  Noticeably the 
distance between the cyclopropyl ring and Trp229 drops under 4 Å in the Y181C  
pocket. The cyclopropyl ring also makes a significant change in its orientation 
towards Tyr183 (Figure 19).  Until now all the contacts observed between the 
alkyl/cycloalkyl inhibitor groups located in wing 2 of the pocket have been over 5 
Å.  This was expected as Tyr183 is involved in pocket formation rather than 
direct binding.  However the cyclopropyl group in 18 moves closer to Tyr183 
(4.73 Å) a drop in distance of almost 3 Å compared to the wt RT pocket (7.59 Å).  
This observation is completely opposite to the trend reported in efavirenz and all 
the docked sultams.  Upon loss of the aromatic Tyr181 to Cys181, these 
inhibitors seem to move towards wing 1.  This was characterized by the decrease 
in distance with Tyr318 and Lys101, as well as the hydrogen bond predictions 
observed in some.  Compound 18, however, reorients itself in the hydrophobic 
region so that it makes more hydrophobic contacts with other aromatic residues 
such as Tyr183.  The cyclopropyl group is popular in drug design due to its 
unique electronic feature.  Cyclopropyl groups have a slight sp2 character 
allowing them to behave as π-systems; therefore, their interactions with aromatic 
rings can be considered π–π interactions. 
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Table 15.  m-Cyclpropylphenyl sultam (18) ligand–residue in Y181C RT pocket. 
 
 
Ligand Residue Distance 
SO2 Lys101 3.34 
Cyclopropyl Cys181 — 
 Tyr183 4.73 
 Tyr188 3.78 
 Trp229 3.98 
Ring C Cys181 — 
 Tyr183 7.88 
 Tyr188 4.21 
 Trp229 5.20 








Figure 19.  m-(Cyclopropylphenyl) sultam (18)  in Y181C RT superimposed with 
efavirenz. 
3-(Isopropylfuranyl) sultam (19) was also docked in wt RT and Y181C RT.  
Compound 19 adopts a similar orientation in the wt pocket as 18.  The isopropyl 
group makes contact with Trp229 at a distance of less than 4 Å. No hydrogen 
bond is predicted, and the distance calculated between the sulfonyl group and 
Lys101 is 3.25 Å.  In general this compound does not have any unique features 
in its binding conformation that sets it apart from the other inhibitors.  Table 16 
and Figure 20 show the results of the docking experiments.  
 In the Y181C RT pocket the most important change noted is the 
orientation of the furan ring oxygen.  After several FlexiDock experiments, the 
oxygen in the furan ring was always oriented towards the SH in Cys181(Table 17 





Table 16.  FlexiDock results for isopropylfuranyl sultam in wt RT. 
 
Ligand Residue Distance 
SO2 Lys101 3.25 
Isopropyl Tyr181 5.74 
 Tyr183 7.72 
 Tyr188 4.63 
 Trp229 3.76 
Ring C Tyr181 6.07 
 Tyr183 9.78 
 Tyr188 4.79 
 Trp229 6.79 


















Table 17.  3-(Isopropylfuranyl) sultam (19) ligand–residue distances  in Y181C 
RT.  
 
Ligand Residue Distance 
SO2 Lys101 3.16 
Isopropyl Cys181 –— 
 Tyr183 7.02 
 Tyr188 5.18 
 Trp229 3.89 
Isopropyl Oxygen Cys181 3.33 
Ring C Tyr183 8.89 
 Tyr188 4.55 
 Trp229 6.72 






















This is almost a 180º rotation from its position in the wt RT pocket.  The distance 
observed between the oxygen and the Cys181 SH is 3.33 Å.  No hydrogen bond 
is predicted; however, the repeated observation of this result in varying 
experiments suggest some sort of interaction occurring.   
D. Modeling of a Rhodium Catalyst  
Mother Nature seems to have mastered the most simple and complex of 
reactions in the most elegant pathways.  Oxidoreductases such as alcohol 
dehydrogenases catalyze transfer hydrogenations to convert carbonyl 
compounds into alcohols using NADH or NADPH as cofactors.145  These 
reactions are usually extremely stereoselective.  However, organic chemists 
have yet to master the ease in which nature can produce enatiomerically pure 
compounds.  Organic synthesis requires economical and practical reagents that 
can be utilized at different reaction scales.  Catalytic-transfer hydrogenation has 
received much attention in recent years. The search for nonhazardous 
enantioselective metal catalysts for transfer hydrogenation dates back to 1976 
when Imai and co-workers reported hydrogen transfer from organic compounds 
to ketone and aldehydes catalyzed by dihydrotetrakis(triphenylphosphine)- 
ruthenium(II) (RuH2(PPh3)4).
146  The process remained primitive and not very well 
understood until recently.  Efforts from Pfalts,147Genet,148 Lemair149 and Evans150 
produced respectable results, but these reactions were limited by their low 
enantioselctivity and catalytic activity, as well as low substrate-to-catalyst ratios 




Figure 22.  Structure of TangPhos ligand. 
 
the low reactivities and enantioselectivities observed in these reactions.122, 145, 151  
 The most recent work in the area of hydrogen-transfer catalysis comes 
from Yang and co-workers.  They use palladium-diphosphane complexes for the 
hydrogenation of N-tosylimines. They found that palladium-TangPhos (Figure 22) 
catalyzed hydrogenations most efficiently compared to other complexes used. 
Reactions proceeded with 99% ee and excellent yields.152  
The saccharin-based synthetic route developed by Baker and co-workers 
(Scheme 3) for the synthesis of a variety of sultams required an enantioselective 
reduction of C=N double bonds.  Mao and Baker found that the commercially 
available RhCp* complex reduces imines into racemic amines under mild 
conditions.  They then developed a chiral Rh catalyst for the asymmetric transfer 
hydrogenation of imines into chiral amines.122  
Pentamethycylopentadienylrhodium chloride was compbined with (1R,2R)-N-(p-
tolunesulfonyl)-1,2-diphenylehthylenediamine [(1R,2R),-TSDPEN] in 
dicholormethane and triethylamine to give the desired complex 20. 1H NMR and 
13C NMR spectroscopy, along with single crystal X-ray crystallography were used 









Figure 23.  Structure of R,R-20 
The best reaction conditions utilized an azeotropic mixture of formic 
acid/triethylamine (5:2) with a 200:1 substrate-to-catalyst (S/C) ratio.  For the 
sultam series the presence of an aryl group on position 3 was found to affect the 
stereoselectivity. R,R-20 gave the S enantiomer when C3 had an aromatic group;  
however, these results were complete opposites when C3 was substituted with a 
methyl or small alkyl group.122  
In order to understand the stereoselectivity of this catalyst, a full 
characterization of the catalytic cycle is needed.  Bragg and co-workers in 
collaboration with Baker and co-workers  were able to propose a catalytic cycle 
through 1D, 2D and variable low-temperature NMR experiments.153  Scheme 14 
shows the catalytic cycle as proposed by Bragg et al.153  The catalytic cycle 
begins with the formation of the activated hydride species. The imine sultam (3-
(aryl)-1,2-benizothiazole 1,1-dioxide) then approaches the catalyst.  Hydrogen 
transfer occurs, and the reduced sultam is bound to the catalyst. The newly 
reduced sultam is then released, and it is thought that the solvent stabilizes the 
ionic rhodium complex formed until another formate ion binds to the metal center 






















































































































Reduced Bound Sultam: 3
Cationic Species: 4 Bound Sultam: 2
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Modeling studies were employed in an attempt to further understand the catalytic 
cylcle and explain the stereoselectivity observed. Employing the same principles 
used in inhibitor/enzyme docking experiments, molecular dynamic studies were 
performed on the docked imine sultam.  
In order to explain the stereoslectivity of the catalyst, a series of imine 
sultams were docked in two different approaches. The “original” and the 
“reverse” approach. The original approach is the conformation leading to the 
enantiomer reported to be the major one produced experimentally.  The reverse 
approach is the conformation leading to the other enantiomer, which was either 
not observed or observed in low yield.122 
The studies reported here present initial results.  A survey of the literature 
indicated that the use of Tripos ff and the SYBYL package in such modeling 
studies is completely novel.  The Tripos ff comes with a set of metal parameters 
typically used in biological systems such as Mg, Ca, Mn and Co.  To be able to 
use the Tripos ff in this project, the rhodium catalyst parameters needed to be 
added to the force field parameter files.  The lack of literature on modeling 
studies for similar rhodium catalysts led to a different approach. 
The basic rhodium parameters were obtained from the Tripos metal 
parameters files that accompany the SYBYL package (Table 18). These 
parameters only supplied the essential information for the force field to recognize 
the atom and include it in calculations.  Second, a search of the Cambridge 
Crystal Structure Database (CCDC) was performed to find different bond angles  
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Table 18.  Rhodium metal parameters from the SYBYL databse. 
Parameter Name Parameter Value 
Mnemonic atom type “Rh” 
Heteroatom Symbol “Rh” 
Valence 6 
Geometry OH (octahedral) 
Equivalent atom type Cr.OH (chromium octahedral) 
Atomic number 45 
Color code Yellow 
Can der Waals radius 1.69 
Formal charge 0 
Electronegativity 2.28 
H–bond Donor NO 
H–bond Acceptor NO 
Lone Pair 0 
Temp factor 9.00 
Atomic weight 102.9.05 
Sybyl 3.x atome type ID 926 
Sybyl 3.x mnemonic atom type “Rh” 
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and bond lengths for similar complexes.  The mean of each value was taken and 
used as a constraint in energy calculations.  This helped guide the Tripos ff and 
stopped illogical and extremely high energy structures from being produced. 
Table 19 lists the mean bond angles and bond lengths from the CCDC search.   
A preliminary study on several crystal structures of similar Rh complexes  
was carried out.  All complexes were subjected to the Tripos ff minimizations, 
and the bond angle and bond lengths were monitored.  Structures with 
unreasonable bond angles or bond lengths, or bent aromatic ring were not used 
in further calculations. Typically these structures have higher energies than the 
other conformations.  The results observed were very encouraging. RMS values 
were never larger than 0.056, and bond angles and lengths did not change too 
much from the values observed in the crystal structures. The focus then turned 
onto the synthetically relevant (R,R)-[TSDPEN]Rh-Cp*-Cl ((R,R)-20).   
The R,R-20 crystal structure was downloaded from the Cambride 
Crystallographic Data Centre (CCDC, code WOLCOP).  Bond constraints were 
only applied for the Rh–Cp* lengths.  Bond-angle values for NH–Rh–NTs, NH–
Rh–Cp*, NTs–Rh–Cp*, Cl–Rh–NH, Cl–Rh–NTs were constrained to the mean 
values in Table 19 . A minimization was performed using the Tripos force field 
and Gasteiger–Hückel charges.  In the first calculation no rigid structures were 
defined.  This led to a strained Rh–Cp* bond and a higher energy than the initial 
crystal energy.  To avoid this problem, the Rh–Cp* bonds were defined as “active 





Table 19.  CCSD bond length and bond angle search results. 
 
Bond Lengths 
















Members of an active aggregate are minimized together as one unit.  This 
was necessary, because the Tripos force field did not have a bond definition for 
the Cp*–Rh bonds.  It is worth noting that constraining bond lengths between 
these two entities was not enough, as the aggregate was needed in order for 
reasonable structures to be produced.  It is important to remember that 
aggregates are not “rigid”, i.e., they do not move.  Figure 24 depicts the crystal 
structure of R,R-20 and its minimized structure superimposed on top of each 
other with an RMS value of 0.055.  Table 20 reports the crystal structure and 
minimized structure bond lengths and bond angles. The initial energy is observed 
to be 504.463 kcal/mol, and the final energy is 338.266 kcal/mol.  Although these 
energy values have no physical meaning, they are used as points of reference.  
Observing an energy drop is good, as this means the calculations are producing 
positive results.   
 Next we substituted the chlorine atom in the crystal structure with a 
hydrogen and ran the same minimization on the R,R-20H (the hydride species is 
the active form of catalyst).  The initial energy of the complex was 676.41 
kcal/mol, and the final energy was 343.54 kcal/mol.  Figure 25 presents the 
minimized R,R-20H superimposed on the R,R-20 crystal structures (RMS = 
0.036) Table 21 compares bond lengths and angles between the crystal structure 
and the hydride species.  Table 21 reports the crystal and minimized hydride 
bond lengths and angles.  The results observed are comparable to those 



















Table 20.  Crystal vs. minimized bond lengths and angles for R,R-20 
 
R,R-Cl    
Bond Lengths Crystal Calculated ∆ 
Rh-NTs 2.186 2.096 0.09 
Rh-NH 2.102 2.064 0.038 
Rh-Cl 2.412 2.188 0.224 
Rh-Cp* 1.832 1.832 0 
NTs-C1 1.473 1.448 0.025 
NH-C2 1.481 1.475 0.006 
Angles    
NTs-Rh-NH 77.27 77.34 -0.07 
Nts-Rh-Cl 94.01 94.01 0 
NH-Rh-Cl 84.09 84.14 -0.05 
Nts-Rh-Cp* 130.26 130.39 -0.13 
NH-Rh-Cp* 129.85 129.97 -0.12 
Nts-C1-C2 108.14 104.96 3.18 
Nh-C2-C1 106.87 110.1 -3.23 
Rh-Nts-C1 113.42 115.71 -2.29 











Figure 25.  R,R-20H (violet) superimposed on R,R-20 after minimization. 
 












Table 21.  Hydride vs. crystal bond lengths and angles. 
 
Bond Lengths Crystal Calculated ∆ 
Rh-Nts 2.186 2.106 0.08 
Rh-NH 2.102 2.079 0.023 
Rh-H (Rh-Cl)2.412 1.025 1.387 
Rh-Cp* 1.832 1.832 0 
Nts-C1 1.473 1.448 0.025 
NH-C2 1.481 1.476 0.005 
Angles    
Nts-Rh-NH 77.27 77.33 -0.06 
Nts-Rh-Cl 94.01 94 0.01 
NH-Rh-Cl 84.09 84.14 -0.05 
Nts-Rh-Cp* 130.26 130.37 -0.11 
NH-Rh-Cp* 129.85 129.95 -0.1 
Nts-C1-C2 108.14 105.15 2.99 
Nh-C2-C1 106.87 110.4 -3.53 







Please note the the crystal contains a Rh–Cl while  the minimized hydride 
catalyst contains Rh–H bond.  It would be expected to observe a significant 
difference between these two bonds.  Our results indicate that the Rh–H bond 
length is 1.025 Å.  The Rh–Cl bond length is almost double that. These results 
are considered acceptable and reasonable.  
The new parameter files for the Tripos force field were loaded.  The 
minimized R,R-20H and 3-(m-methylphenyl)-1,2-benzisothiazole 1,1-dioxide (21) 
were retrived (Figure 26).  
Compound 21 (refered to as imine sultam) was docked into the catalyst 
cavity using the Dock program in SYBYL.  The Dock program is a manual 
docking program.  The “enzyme”/catalyst and inhibitor are each identified.  The 
catalyst was then fixed in space, and the inhibitor’s position was adjusted into the 
cavity. An interactive dialogue box keeps track of steric and electrostatic energies 
as the inhibitor’s position is adjusted.  The imine substrate position was adjusted 














Two docking experiments were carried out.  In the first docking 
experiment,  the imine sultam is positioned so that its sulfonyl group is towards 
the catalyst NH2 moiety (Figure 26 A).  In the second experiment the sulfonyl 
group is docked toward the N–Ts moiety; this conformation will be refered to as 
“reverse” (Figure 26 B). Yamakawai and co-workers published two studies that 
dealt with chiral η6–arene–ruthenium(II) complexes.154, 155  In molecular orbital 
calculations they attempted to identify the mechanisms of action by which 
asymmetric transfer hydrogenation of carbonyl compounds catalyzed by these 
complexes proceed.154  They also performed density functional theory-based 
(DFT) studies to shed some light on the origin of enantioselectivity in these 
reactions.155  Based on their DFT studies they predicted that in aryl ketones CH/π 
interactions between the arene ring and aryl ketone are the basis of 
enantioselectivity. According to their findings the R,R-catalyst gives the R alcohol 
and vice versa.  The rhodium catalyst in question affords the exact opposite 
selectivity in imine reductions, especially when a bulky aromatic ring exists on 
ring C. (Refer to figure 6.) 
In the original approach in the docking experiment, it is assumed that 
CH/π interactions do occur. The “reverse” docking conformation assumes that no 
π interactions govern enantioselectivity.  The substrate/catalyst complex is then 
converted to a FlexiDock input file.  This is only done to create a file with both 
catalyst and substrate in the same molecular area. This is essential in order to be 
able to minimize the complex as one unit.  A molecular dynamics experiment is 






















Figure 27.  (A) imine substrate docked into R,R-20H. (B) imine substrate docked 
in “reverse” mode 
A 
B 
Final E = 331.175 kcal/mol 
       Final E = 340.93 kcal/mol 
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constrains as before. The energies between the two possible substrate 
approaches are reported and compared.  Figure 27 displays both docked 
conformations with the final energies for each.  The final energy of the docked 
imine sultam is lower than that of the “reverse” conformation, with a difference of 
~10 kcal/mol observed between these two complexes.  The first complex leads to 
the S stereochemistry on the sultam while the second leads to the R.   
Experimentally, the S enantiomer is the major product isolated from this 
reaction.  The energy difference observed could explain why the original 
approach is preferred.  The R or “reverse” approach is relatively higher in energy 
and therefore is expected to be a minor contributing structure along the 
conversion pathway. 
 Next n-butylimine (22) and methyl imine (23) (Figure 28) were docked into 
the catalyst cavity in both the “original” approach and the “reverse approach.  
The energy of the first approach which leads to the R enantiomer is 126 kcal/mol, 
and the energy of the “reverse” approach is 117 kcal/mol, which is a difference of 
9 kcal/mol.  For a small molecule system a change of ~10 kcal is considered 
significant.   Based on these observations the R enantiomer should produce the 
major product.  Indeed this is observed experimentally (Figure 29 and Figure 30 
show both approaches).122    
 Compound 23’s results also matched its experimental observation.  The 
“reverse” approach produced the lowest complex energy. This approach leads to 
the formation of the R enantiomer a result that agrees with the experimental 





























































Final E = 126.369 kcal/mol 
 























Figure 30.  Methyl imine sultam in R,R-20H (A) original approach; (B) reverse 
approach.  
 
Final E = 132.517 kcal/mol 
 
A 





3-(Cyclopropylethynyl)-1,2-benzisothiazole 1,1-dioxide was also docked  
into the catalyst cavity.  Figure 31 shows both original and “reverse” approach. 
The calculated energy for the original approach is 441.23 kcal/mol and for the 
reverse approach 434.62 kcal/mol. Based on the pattern observed in the 
previous docking experiments, the R stereochemistry should be preferred.  
However, synthetic studies yielded products with no optical activity, which 
indicates that the catalyst did not enantioselectively reduce the imine bond.  
Moreover, for the cyclopropyl and cyclobutyl analogues, the alkyne was also 
reduced to the alkane.  The tert-butyl analogue was found to be optically inactive; 
however, its triple bond remained intact.  This is probably due to steric hindrance 
as the tert-butyl group is bulkier than the small ring structures.  
The modeling studies presented above are considered only initial 
modeling studies.  We used these compounds to establish the best parameters 
for such experiments.  It was very disappointing to find that not only did the 
catalyst not reduce the alkylethynyl sultam series stereoselectively, but it also 
reduced the alkyne bond into an alkyl bond for two out of three of the target 
compounds.  It is clear from the experimental results that the approach of 
substrate to catalyst is greatly governed by steric effects.  In the future further 
mechanistic studies are needed. A study of different substrates with a wide 
variety of substituents at C-3 is also required in order to determine when the 
catalyst exactly switches from stereoselectively producing S to producing 
racemic mixture, to stereoselectively producing R.    
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Final E = 441.23 






















Figure 31.  Cyclopropylethynyl imine sultam in catalyst cavity. (A) direct 
approach; (B) reverse approach. 
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III.  Experimental 
 
Preparation of 3-(chloro)-1,2-benzisothiazole 1,1-d ioxide  (1) 
In a dry round bottom flask equipped with a stir bar and an air condenser were 
placed 4.05 g (22.1 mmol) of saccharin and 5.88 g (28.6 mmol) of PCl5.  The 
apparatus was fitted with an inlet nitrogen line and an outlet vent to allow release 
of gas build up  into the fume hood and the mixture was heated to 80 ºC.  Once 
the reaction changed from cloudy to clear, the temperature was raised to 175 ºC 
for 2 h.  At the end of the 2-h period, the reaction mixture was cooled to 100 ºC 
and a vacuum was applied to remove the POCl3.  The reaction was left to cool to 
room temperature while under vacuum and when at room temperature the 
vacuum was maintained for another 1 h.  A pale yellow solid formed.  It was 
recrystallized from hot toluene to give a white fluffy solid (3.5 g, 79% yield): mp 
(139-143 ºC; lit. 140–144) 1H-NMR (300 MHz, CDCl3, 25 ºC): δ 7.8–8.4 ppm (m, 
4H, aromatic).  13C NMR (300 MHz, CDCl3, 25 ºC): δ 166 (C3), 140.5 (C9), 134.9 
(C8), 134.4(C7), 129.8 (C4) 125.1 (C5), 122.5 (C8). 
3-Ethynylalkyl 1,2-benzisothizoles 1,1-dioxides 
In a dry flask was dissolved 2.0 mmol of the respective alkyne in 6 mL of freshly 
dried THF. The solution was stirred and cooled to −78 ºC under anhydrous 
conditions and a nitrogen atmosphere.  One equivalent of 2.2 M n-BuLi solution 
in THF (0.9 mL) or 1.6 M MeLi in THF (1.25 mL) were then added via a syringe.  
The reaction was left to stir for 4 h and then warm to −40 ºC.  It was then cooled 
to −78 ºC, and a solution of 0.643 g (1.5 equiv.) 3-chloro-1,2-benzisothiazole 1,1-
dioxide in dry THF was quickly poured into the reaction.  The flask was refitted 
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with a septum and a nitrogen line, and the coupling reaction mixture was left to 
stir at −78 ºC for 1 h. It was monitored by TLC.  After 1 h , 5 mL of satd aq NH4Cl 
was added to quench the reaction at −78 ºC.  The mixture was left to warm to 
room temperature overnight, and a white precipitate formed.  The biphasic 
mixture was then filtered and separated.  The organic layer was washed with 1.0 
M NaHCO3 (2 x 5 mL).  It was dried over anhyd. MgSO4, vacuum filtered and 
rotary evaporated.  The desired product was purified using silica gel column 
chromatography eluting with a gradient solvent system starting with 5% acetone 
in petroleum ether to 10% acetone in petroleum ether (for the butylethynyl 
analogues 4 and 5) or 15% acetone in petroleum ether (for the cyclopropylethnyl 
analogue 3). 
3-(Cyclopropylethynyl)-1,2-benzisothiazole 1,1-diox ide (3) 
Yield: 0.177 g (40% yield). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.89–7.73 (m, 
4H, CH, ArH), 1.64–1.74 (m, 1H, CH-cyclopropyl), 1.10–1.21 (m, 4H, CH2-
cyclopropyl). 
13C NMR (300 MHz, CDCl3, 25 ºC): δ 156.54 (C-3, C=N), 138.71 (C-9, CH, Ar), 
133.86 (C-6, Ar), 133.74 (C-7, Ar), 131.36 (C-4, Ar), 125.04 (C-5, Ar), 122.11 (C-
8, Ar), 115.77 (C-1', alkyne), 68.79 (C-2', alkyne), 10.97 (C-4',C-5', cyclopropyl), 
1.11 (C-3', cyclopropyl). HRMS-APPI (m/z): [M+H]+ calcd for C12H10NO2S, 
232.0432; found, 232.0424. 
3-(tert-Butylethynyl)-1,2-benzisothiazole 1,1-dioxide (4)  
Yield: 0.140 g (47% yield). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.92–7.68 (m, 
4H, CH, ArH), 1.46 (s, 9H, CH3, t-butyl). 
13C NMR (300 MHz, CDCl3, 25 ºC): δ 
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156.81 (C-3, C=N), 138.68 (C-9, CH, Ar), 133.97 (C-6,CH, Ar), 133.82 (C-7, 
CH,Ar), 131.31 (C4,CH, Ar), 125.05 (C-8, Ch, Ar), 122.11 (C-5, CH, Ar, 118.59 
(C-2′, C≡C), 71.51 (C-1′, C≡C), 29.95 (3CH3, t-Bu), 28.99 (-C(CH3)3, t-But). 
HRMS-APPI (m/z): [M+H]+ calcd for C13H14NO2S, 248.0745; found, 248.0731. 
3-(Cyclobutylethynyl)-1,2-benzisothizoles 1,1-dioxi de (5) 
Yield: 0.185 g (43% yield). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.9–7.60 (m, 4H, 
CH, ArH), 3.31–3.29 (m, 1H, CH-cyclobutyl), 2.24–1.80 (m, 6H, CH2-cyclobutyll). 
13C NMR (300 MHz, CDCl3, 25 ºC): δ 157 (C-3, C=N), 138.59 (C-9, CH, Ar), 
133.99 (C-6, Ar), 133.89 (C-7, Ar), 131.26 (C-4, Ar), 125.015(C-5, Ar), 122.10 (C-
8, Ar), 114.23.77 (C-1', alkyne), 89.01 (C-2', alkyne), 19.42–18.16(C-4',C-5', C-6′, 
cyclobutyl , 0.97 (C-3', cyclobutyl).  HRMS-APPI (m/z): [M+H]+calcd for 
C13H14NO2S, 245.051; found, 245.062. 
3-(Cyclopropylethyl)-2,3-dihydrdo-1,2-benzisothiazo le 1,1-dioxide (6) 
In a dry round-bottom flask equipped with a stirring bar and a nitrogen line was 
dissolved 1.9 mg of (R,R)-[TSDPEN]RhCp* in 1 mL of dry dichloromethane and 
0.05 mL of an azeotropic mixture of HCOOH:Et3N (5:2) . The mixture was stirred 
for ten min.  A solution of 3-(cyclopropylethynyl)-1,2-benzisothiazole 1,1-dioxide 
(140 mg 0.606 mmol) in 1 mL dry dicholoromethane, and 0.05 mL of azeotrope 
were added.  The reaction was monitored by TLC. After 30 min, no product 
formation was observed.  Another aliquote of the azeotrope (0.1 mL) were 
added, and the reaction mixture was stirred for another 30 min, and product 
formation was observed at this time.  Over the course of 2 h a total of 0.6 mL of 
azeotrope was added, and TLC were taken at 15-min intervals. Upon 
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disappearance of all starting material, the reaction was quenched with 1 M 
NaHCO3 (aq.).  The two layers were separated, and the organic layer was dried 
over anhyd MgSO4, vacuum filtered and evaporated under reduced pressure to 
give a dark-red residue. Purification by silica gel column chromatography in a 
gradient solvent system from 5% acetone in pet ether15% acetone in pet ether 
(this concentration was held until the first spot was isolated) 20% acetone in 
pet ether (product eluted with this concentration) gave the desired product in 
50% yield (70 mg). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.81–7.36 (4H, CH, 
ArH), 5.45 (1H,s, NH), 5.13 (m,1H, CH, J = 3.9, J = 9.3, CH),  3.26–3.03 (m, 2H, 
CH2(1′), J = 3.6 Hz, J = 9.6 Hz, Jgem= 18 Hz), 1.95 (m, 1H, CH in cycloropyl, J = 
4.5, J = 1.5), 1.15–1.11 (m, 2H, CH2(2′),J = 4.5) 0.99–0.95 (dt, 2H, CH2 in 
cyclopropyl, J = 3.6, J = 4.5), 0.89-0.84 (m, 2H, CH2 in cyclopropyl). 
13C NMR 
(300 MHz, CDCl3, 25 ºC): δ 138.61 (C-4, CH, Ar), 135.60 (C-9, Ar), 133.11 (C-6, 
Ar), 129.36 (C-8, Ar), 123.88 (C-5, Ar), 121.55 (C-7, Ar), 52.90 (C-3), 48.95 (C-
1′), 21.06 (C-2′), 14 (CH, cyclopropyl), 11.71–11.61 (2CH2, cyclopropyl). HRMS-
APPI (m/z): [M+H]+ calcd for C12H15NO2S, 238.0902; found, 238.0907. 
3-(tert-Butylethynyl)-2,3-dihydro-1,2 benzisothiazole 1,1- dioxide (7) 
In a dry round-bottom flask equipped with a stirring bar was dissolved 1.6 mg of 
R,R-[TSDPEN]RhCp* in 1 mL of freshly dried dichloromethane and 0.047 mL of 
HCOOH:Et3N azeotrope (1 equiv of formic acid to 1 equiv of catalyst) The 
mixture was stirred for 10 min at room temperature, then a solution of 3-(tert-
butylethynyl)-1,2-benzisothizole 1,1-dioxide, 120 mg (0.485 mmol) in 1 mL of 
CH2Cl2 and 0.047 mL of azeotrope were added. The reaction was monitored by 
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TLC, and after 30 min product was already forming.  Over the course of 2.5 h a 
total of 0.6 mL of azeotrope was added in increments of 0.1 mL at 30 min 
intervals.  TLC were taken every 15 min. At 2.5 h the TLC indicated completion of 
the reaction.  The reaction was quenched with 1 M NaHCO3 (aq). The biphasic 
mixture was separated, and the organic layer was dried over anhyd MgSO4, 
vacuum filtered and rotary evaporated to give a dark red-residue.  Column 
chromatography using a gradient solvent system starting with 5% acetone in pet 
ether  15% acetone in pet ether (this was held until the first spot was 
completely eluted) 20% acetone in pet ether until the desired product was 
collected.  Rotary evaporation gave the desired product as a white solid in 61% 
yield (40 mg).  1H NMR (300 MHz, 25 ºC, CDCl3: δ 7.70–7.91 (m, 4H, CH, ArH), 
6.2 (s,1H, CH), 1.25 (s, 9H, -C(CH3)).  
13C NMR : δ 151.00 (C-4), 135.42 (C-9), 
133.42 (C-6), 133.09 (C-8), 129.92 (C-7), 122.65 (C7), 121.82 (C2′, C≡C), 89.54 
(C1′, C≡C), 41.77 (C3), 27.04 (3 CH3, t-Butl), 0.98 (C3′, t-But). HRMS-APPI 
(m/z): [M-H]+ calcd for C13H14NO2S, 248.074; found, 248.072. 
3-(Cyclobutylethyl)-2,3-dihydro-1,2benzisothiazole 1,1-dioxide (23) 
(R,R)-[TSDPEN]RhCp* (1.15 mg, 0.002 mmol) were dissolved in dry 
dicholoromethane under anhydrous conditions and a nitrogen atmosphere. An 
azeotropic mixture of HCOOH:Et3N (5:2) (0.034 mL) was added via a micro 
syringe.  The reaction was stirred for 10 min, then a solution of 3-
(cyclobutylethynyl)-1,2-benzisothiazole 1,1-dioxide (5) (89 mg, 0.36 mmol) in 1 
mL of dichloromethane and 0.034 mL of azeotrope was added.  Reaction 
progress was monitored by TLC, and product started forming around 35 min. 
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Over the course of 2.5 h 0.1 mL increments were added at 30-min intervals while 
TLCs were taken every 15 min.  Upon disappearance of all starting material, the 
reaction was quenched with 1 M NaHCO3 (aq).  The two layers were then 
separated, and the organic layer was dried over anhyd MgSO4.  It was then 
vacuum filtered, and the solvent was removed under reduced pressure to give a 
dark-red residue.  Silica gel column chromatography using a gradient solvent 
system from 5% acetone in petroleum ether to 15% acetone in petroleum ether 
gave 79 mg (60%) of the desired product.  1H NMR (300 MHz, CDCl3, 25 ºC): δ 
7.99–7.24 (4H, CH, ArH), 5.95 (1H,s, NH), 5.20 (m,1H),  3.95–3.1(m, 2H, 
CH2(1′),  2.95 (m, 1H, CH in cyclobutyl) 2.1–1.1 (m, 4CH2, CH2(2′), 3CH2 in 
cyclobutyl ). 13C NMR (300 MHz, CDCl3, 25 ºC): δ 138.61 (C-4, CH, Ar), 135.60 
(C-9, Ar), 133.10 (C-6, Ar), 129.33 (C-8, Ar), 123.80 (C-5, Ar), 121.45 (C-7, Ar), 
56.89 (C-3), 48.95 (C-1′), 21.06 (C-2′), 29.02 (CH, cyclobutyl), 19.42–18.16 
(3CH2, cyclobutyll). HRMS-APPI (m/z): [M+H]
+ calcd for C13H17NO2S, 251.098; 
found, 250.969. 
3-(Alkylethynyl)-2,3-dihydro-2-methyl 1,1-dioxide  
The respective 3-(alkylethynyl)-2,3-dihydro-1,2-benisothiazole 1,1-dioxide was 
dissolved in dry N-N-dimethylformamide or dry acetonitrile under anhydrous 
conditions and a nitrogen atmosphere.  Cs2CO3 (1.5 equiv) were added, and the 
reaction mixture was then stirred at room temperature for 1 h.  Excess amount of 
MeI was added via a syringe, and the reaction was then stirred at room 
temperature for 1 h. It was monitored by TLC (25% acetone in petroleum ether). 
Upon disappearance of the starting material, the reaction was quenched with 
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water.  The mixture was concentrated under high vacuum to give a yellow oil with 
a white precipitate.  The residue was taken up in 5 mL dichloromethane and 
washed with water (3 x 5 mL).  The organic layer was then dried over anhydrous 
MgSO4, and vacuum filtered, and the solvent was rotary evaporated under 
reduced pressure to give a yellow oil.  Flash column chromatography with 15%–
20% acetone in petroleum ether afforded the desired products in quantitative 
yields. 
3-(Cyclopropylethyl)-2,3-dihydro-2-methyl 1,1-dioxi de (9) 
 Yield: 35 mg, 90% 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.32–7.8 (m, 4H, CH, 
ArH), 4.97–4.90 (t, 1H, CH(3)), 3.3-2.96 (m, 2H, CH2(2′), 2.90 (m, 3H, N–CH3), 
2.0-1.9 (m, 1H, CH in cyclopropyl), 1.2–1.1 (m, 2H, CH2(2′)), 1.85–0.95 (m, 4H, 
2CH2 in cyclopropyl). 
13C NMR (300 MHz, CDCl3, 25 ºC): δ 138.13 (C-9, CH, Ar), 
134.51 (C-6, Ar), 133.01 (C-7, Ar), 129.35 (C-5, Ar), 124.24 (C-4, Ar), 121.35 (C-
8, Ar), 58.64 (C-3), 47.46 (N-CH3), 29.59 (C-1′), 21.37 (C-2′), 18.00 (CH, 
cyclopropyl), 11.71-11.61 (2CH2, cyclopropyl). HRMS-APPI failed after several 
trials. Compound would not ionize. 
3-(tert-Butylethynyl)-2,3-dihydro-2-methyl 1,1-dioxide(10)  
Yield: 40 mg, 89% 1H NMR (300 MHz, CDCl3, 25 ºC): δ 9.13-9.12 (d,1H, CH, Ar), 
7.86-7.85 (m, 3H, CH, ArH), 6.13 (s,1H, CH(3), 10b), 5.91 (s,1H, CH(3), 10a), 
3.21 (s, 3H, N-CH3, 10b), 3.18 (s,3H,N-CH3,10b), 1.2 (s, 9H, 3CH3, t-butyl).  
13C 
NMR (300 MHz, CDCl3, 25 ºC): δ 133.87 (C-9), 133.57 (C-6), 132.17 (C-8), 
129.00 (C-7), 122.65 (C7), 99.17 (C2′, C≡C), 94.73 (C1′, C≡C), 41.71 (C3 10a or 
10b), 44.21 (C3, 10a or 10b), 29.69 (N-CH3) 27.12 (3 CH3, t-butyl), 0.98 (C3′, t-
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butyl). HR MS-APPI (m/z): [M+H]+ Calcd for C14H16NO2S, 262.0902; found 
262.0933. 
3-(Cyclobutylethynyl)-2,3-dihydro-1,2-benzisothiazo le (11). 
Yield: 20 mg , 60%. 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.80–7.41 (4H, CH, 
ArH), 5.20 (m,1H),  3.85–3.1(m, 2H, CH2(1′),  2.95 (m, 1H, CH in cyclobutyl), 
2.89 (s, 3H, N-CH3) 2.1–1.1 (m, 4CH2, CH2(2′), 3CH2 in cyclobutyl ). 13C NMR 
(300 MHz, CDCl3, 25 ºC): δ 137.61 (C-4, CH, Ar), 135.50 (C-9, Ar), 133.20 (C-6, 
Ar), 129.33(C-8, Ar), 123.80 (C-5, Ar), 121.45 (C-7, Ar), 57.99 (C-3), 48.95 (C-1′), 
21.06 (C-2′), 29.02 (CH, cyclobutyl), 19.42–18.16 (3CH2, cyclobutyll). APPI failed 
after several attempts. The expected m/z of 280.137 was not observed, the 
spectrum only had background.  
2,3-Dihydro-3,3-dialkylethynyl-1,2-benzisothizoles 1,1-dioxide 
Method A. 
In a dry flask under anhydrous conditions and a nitrogen atmosphere were 
dissolved 2.0 mmol of the respective alkyne. 1 equivilant of 2.2 M n-BuLi (0.9 
mL) or 1.6 M MeLi (1.25 mL) were added via a syringe at -78 ºC. The reaction 
was left to stir for four h while it warmed to -40 ºC.  0.9 mmol (0.165 g)of 
saccharin (0.45 equivalents) were dissolved in dry THF and added dropwise over 
a period of 30 min.  The reaction was then left to warm up to r.t over night.  It was 
then cooled to 0 ºC and quenched with saturated NH4Cl (aq.).  The biphasic 
mixture was filtered, and the organic layer separated.  It was washed with 1 M 
NaHCO3 (2 x 5 mL) and dried over anhydrous MgSO4.  Rotary evaporation 
afforded the bis-alkylated sultam in low yields (15-30%yield). 
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Method B. 
In a dry flask under anhydrous conditions and a nitrogen atmosphere were 
dissolved 2.0 mmol of the respective alkyne. 1 equivialnt of 2.2 M n-BuLi (0.9 
mL) or of 1.6 M MeLi (1.25 mL) were added via a syringe at -78 ºC.  The reaction 
was left to warm to -40 ºC over the course of four h.  A solution of 3-chloro-1,2-
benzisothizole 1,1-dioxide in THF (2 mmol, 0.402 g, 1 equivilant), were added 
slowly over the course of 30-40 min at -78 ºC.  The reaction was then left to 
warm again to -40 ºC. It was then quenched with saturated NH4Cl (aq); the 
mixture was filtered then separated.  The organic layer was then washed with 1 
M NaHCO3 (aq), then dried over anhydrous MgSO4.  Vacuum filtration followed 
by rotary evaporation gave the desired products as crystalline solids in moderate 
yields. 
2,3-Dihydro-3,3-dicyclopropyllethynyl-1,2-benzisoth izoles 1,1-dioxide 
(12) 
Yield: 0.130 g, 60%. 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.74-7.754 (m, 4H, CH, 
ArH), 5.0 (s, 1H, NH), 1.29-1.2 (m, 2H, 2CH from cyclopropyl), 0.81-0.68 (m, 8H, 
4CH2 from cyclopropyl).  
13C NMR (300 MHz, CDCl3, 25 ºC): δ 140.97 (C-9, CH, 
Ar), 134.26 (C-6, Ar), 133.63 (C-7, Ar), 130.36 (C-5, Ar), 125.21 (C-4, Ar), 121.21 
(C-8, Ar), 88.76 (C-2′, C≡C), 72.39 (C-1′, C≡C), 52.27 (C-3), 8.37 (4CH2 
cylopropyl), -0.59 (2CH cyclopropyl). HR MS-APPI (m/z): [M+H]+ calcd for 
C17H16NO2S 298.0902, found 298.0906. 
2,3-Dihydro-3,3-dicyclobutylethynyl-1,2-benzisothiz oles 1,1-dioxide 
(13) 
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Yield: 0.150 g, 67% 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.76-7.55 (m, 4H, CH, 
ArH), 3.09-2.90 (m, 1H, CH from cyclobutyl), 2.26-1.82 (m, 6H, 3CH2 from 
cyclobutyl). 13C NMR (300 MHz, CDCl3, 25 ºC): 140.91 (C9, Ar), 134.03 (C-6, Ar), 
133.37 (C-7,Ar), 130.09 (C-5), 124.98 (C-4,Ar), 120.95 (C-8,Ar), 89.09 (C-2′, 
C≡C), 78.07 (C-1′, C≡C), 52.38 (C-3), 29.28-29.27 (2CH2, cyclobutyl ring), 24.61 
(CH, cyclobutyl), 19.13 (CH cyclobutyl). HR MS-APPI (m/z): [M+H]+ calcd for 
C19H20NO2S 326.1215, found326.1223. [M-H]
+ calcd for C19H18NO2S 324.1058 
found, 324.1471. 
3,3-(di- tert-butylethynyl)-2,3-dihydro-1,2-benistohiazole 1,1-d ioxide (14) 
Yield: 0.110 9, 70%. 1H NMR (300 MHz, CDCl3, 25 ºC): δ 8.21-7.41 (m, 4H, CH, 
ArH), 1.26 (s, 9H, t-butyl). 13C NMR (300 MHz, CDCl3, 25 ºC): δ 140.31 (C-4), 
139.15 (C-9), 132.89 (C-6), 130.28 (C-8), 129.92 (C-5), 129.00 (C-7), 95.15 (C-
2′, C≡C), 79.69 (C-1′, C≡C), 66.14 (C-3), 30.29 (CH3, t-butyl), 27.58 (C-3′, t-
butyl).  HR MS-APPI (m/z): [M+H]+ calcld for C19H24NO2S 330.1528, found 
330.1534. 
2,3-Dihydro-2-methyl-3,3-(di- t-butylethynyl)-1,2-benzisothizoles 1,1-dioxide 
(15) 
In a flame dried flask 0.205 g (0.62 mmol) of (14) and 0.303 g (0.93 mmol, 1.5 
equiv.) of Cs2CO3 were dissolved in freshly dried acetonitrile under anhydrous 
conditions and a nitrogen atmosphere. The reaction was stirred at r.t. for one 
hour then excess amount of MeI (0.1 mL, 3 mmol) were added via a syringe.  
The  progress of the reaction was monitored by TLC. Upon disappearance of the 
starting material, the mixture was concentrated under reduced pressure to give a 
 146 
yellow oil and a white precipitate. The mixture was suspended in 
dicholormethane and the organic layer was washed with water ( 3x 10 mL) and  
dried over anhydrous MgSO4. Vacuum filtration, followed by rotary evaporation, 
then high vacuum rotary evaporation gave a pale yellow oil. Flash column 
chromatography with 15% acetone in petroleum ether afforded the desired 
product in qualitative yield (0.200 g).  1H NMR (300 MHz, CDCl3, 25 ºC): δ 8.36-
7.4 (m, 4H, CH, ArH), 2.9 (s, 3H, N-CH3), 2.25 (s, 18H, 6CH3 t-butyl). 
13 C NMR 
143.03 (C-9), 137.12 (C-4), 132.41 (C-6), 129.92 (C-8), 129.54 (C-5), 128.55 (C-
7), 94.79 (C-2′,C≡C), 79.09 (C-1′,C≡C), 65.62 (C-3), 37.75 (N-CH3), 30.39 (-
C(CH3)3, 2 t-butyl), 27.49 (-C(CH3)). HRMS-APPI (m/z): calcd for C20H26NO2S 
343.1606 found  
2,3-Dihydro-2-methyl-3,3-(dicyclobutyllethynyl)-1,2 -benzisothizoles 1,1-
dioxide (16). 
In a dry round-bottom flask 83 mg (0.255 mmol) and 125 mg (0.383 mmol , 1.5 
equiv.) were dissolved in dry acetonitrile under anhydrous conditions and a 
nitrogen atmosphere. The mixture was stirred at r.t. for one hour, then an excess 
amount of MeI (108 mg, 0.048 mL, 3 equiv) were added via a syringe.  The 
reaction was monitored by TLC. Upon disappearance of starting material, it was 
rotarty evaporated to give a yellow oil and white precipitate. The residue was 
taken up in 10 mL of dichloromethane and washed with water (3 x 5 mL). The 
organic layer was then collected, dried over anhydrous MgSO4 and vacuum 
filtered.  It was concentrated under reduced pressure and high vacuum pressure 
to give a pale yellow crystalline solid.  Flash chromatography using 15% acetone 
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in petroleum ether gave the desired product in quantitative yield as a while 
crystalline solid (85 mg).  1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.78-7.75 (4H, 
CH, ArH), 3.07-2.81 (m, 2H, 2CH from cyclobutyl), 2.99 (s, 3H, CH3), 2.26-1.83 
(m, 12H, 3CH2) from cyclobutyl). HRMS-APPI(m/z): [M+H]
+ calculated for 
C20H22NO2S 339.1293, found 339.1298 
3,3-(Dicyclopropylethynyl)-2,3-dihydro-2-methyl-1,2 -benzisothizoles 1,1-
dioxide (12)  
In a flame dried round-bottom flask 89mg (0.329 mmol) and 161 mg (0.495 mmol 
, 1.5 equiv.) were dissolved in dry acetonitrile under anhydrous conditions and a 
nitrogen atmosphere. The mixture was stirred at r.t. for one hour, then an excess 
amount of MeI (108 mg, 0.048 mL, 3 equiv) were added via a syringe.  The 
reaction was monitored by TLC. Upon disappearance of starting material, it was 
rotarty evaporated to give a yellow oil and white precipitate. The residue was 
taken up in 10 mL of dichloromethane and washed with water (3 x 5 mL). The 
organic layer was then collected, dried over anhydrous MgSO4 and vacuum 
filtered.  It was concentrated under reduced pressure and high vacuum pressure 
to give a pale yellow crystalline solid.  Flash chromatography using 15% acetone 
in petroleum ether gave the desired product in quantitative yield as a while 
crystalline solid (160 mg). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.64-7.44 (m, 4H, 
CH, ArH), 2.98 (s, 3H, N-CH3) ,1.91-1.21 (m, 2H, 2CH from cyclopropyl), 0.81-
0.68 (m, 8H, 4CH2 from cyclopropyl).  
13C NMR (300 MHz, CDCl3, 25 ºC): δ 
140.87 (C-9, CH, Ar), 134.16 (C-6, Ar), 133.63 (C-7, Ar), 130.36 (C-5, Ar), 125.11 
(C-4, Ar), 121.21 (C-8, Ar), 88.76 (C-2′, C≡C), 72.39 (C-1′, C≡C), 55.27 (C-3), 
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30.41 (N-CH3) 8.37 (4CH2 cylopropyl), -0.59 (2CH cyclopropyl).HRMS-APPI 
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 1H NMR of 3-(cyclopropylethyl)-2,3-dihydro-2-methyl-1,2-























1H NMR of 3-(tert-butylethynyl)-2,3-dihydro-2-methyl-1,2-












13C NMR of 3-(tert-butylethynyl)-2,3-dihydro-2-methyl-1,2-

























13C NMR of 3,3-bis(cyclopropylethynyl)-2,3-dihydro-1,2-












1H NMR of 3,3-bis(cyclobutylethynyll)-2,3-dihydro-1,2-












13C NMR of 3,3-bis(cyclobutylethynyl)-2,3-dihydro-1,2-



































13C NMR of 3,3-bis(tert-butylethyny)-2,3-dihydro-1,2-benzisothiazole 1,1 dioxide 
 1H NMR of 3,3-bis(cyclopropylethynyl)-2,3-dihydro-2-methyl-1,2-




































1H NMR of 3,3-bis(tert-butylethynyl)-2,3-dihydro-2-methyl-1,2-






1H NMR of 3,3-bis(cyclobutylethynyl)-2,3-dihydro-2-methyl-1,2-














13C NMR of 3,3-bis(cyclobutylethynyl)-2,3-dihydro-2-methyl-1,2-
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